<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Haematol</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Haematol</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1365-2141</journal-id><journal-id journal-id-type="publisher-id">BJH</journal-id><journal-title-group><journal-title>British Journal of Haematology</journal-title></journal-title-group><issn pub-type="ppub">0007-1048</issn><issn pub-type="epub">1365-2141</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26205622</article-id><article-id pub-id-type="pmc">4737125</article-id><article-id pub-id-type="doi">10.1111/bjh.13613</article-id><article-id pub-id-type="publisher-id">BJH13613</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Paper</subject></subj-group><subj-group subj-group-type="heading"><subject>Paediatrics</subject></subj-group></article-categories><title-group><article-title>Distinctive genotypes in infants with T&#x02010;cell acute lymphoblastic leukaemia</article-title><alt-title alt-title-type="left-running-head">M. B. Mansur <italic>et&#x000a0;al</italic></alt-title></title-group><contrib-group><contrib id="bjh13613-cr-0001" contrib-type="author" corresp="yes"><name><surname>Mansur</surname><given-names>Marcela B.</given-names></name><xref ref-type="aff" rid="bjh13613-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="bjh13613-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="bjh13613-cr-0002" contrib-type="author"><name><surname>van Delft</surname><given-names>Frederik W.</given-names></name><xref ref-type="aff" rid="bjh13613-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="bjh13613-cr-0003" contrib-type="author"><name><surname>Colman</surname><given-names>Susan M.</given-names></name><xref ref-type="aff" rid="bjh13613-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="bjh13613-cr-0004" contrib-type="author"><name><surname>Furness</surname><given-names>Caroline L.</given-names></name><xref ref-type="aff" rid="bjh13613-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="bjh13613-cr-0005" contrib-type="author"><name><surname>Gibson</surname><given-names>Jane</given-names></name><xref ref-type="aff" rid="bjh13613-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="bjh13613-cr-0006" contrib-type="author"><name><surname>Emerenciano</surname><given-names>Mariana</given-names></name><xref ref-type="aff" rid="bjh13613-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="bjh13613-cr-0007" contrib-type="author"><name><surname>Kempski</surname><given-names>Helena</given-names></name><xref ref-type="aff" rid="bjh13613-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="bjh13613-cr-0008" contrib-type="author"><name><surname>Clappier</surname><given-names>Emmanuelle</given-names></name><xref ref-type="aff" rid="bjh13613-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="bjh13613-cr-0009" contrib-type="author"><name><surname>Cave</surname><given-names>H&#x000e9;l&#x000e8;ne</given-names></name><xref ref-type="aff" rid="bjh13613-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="bjh13613-cr-0010" contrib-type="author"><name><surname>Soulier</surname><given-names>Jean</given-names></name><xref ref-type="aff" rid="bjh13613-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="bjh13613-cr-0011" contrib-type="author"><name><surname>Pombo&#x02010;de&#x02010;Oliveira</surname><given-names>Maria S.</given-names></name><xref ref-type="aff" rid="bjh13613-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="bjh13613-cr-0012" contrib-type="author"><name><surname>Greaves</surname><given-names>Mel</given-names></name><xref ref-type="aff" rid="bjh13613-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="bjh13613-cr-0013" contrib-type="author" corresp="yes"><name><surname>Ford</surname><given-names>Anthony M.</given-names></name><xref ref-type="aff" rid="bjh13613-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="bjh13613-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Centre for Evolution and Cancer</named-content><institution>The Institute of Cancer Research</institution><named-content content-type="city">London</named-content><country country="GB">UK</country></aff><aff id="bjh13613-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">Paediatric Haematology&#x02010;Oncology Program, Research Centre</named-content><institution>Instituto Nacional de C&#x000e2;ncer</institution><named-content content-type="city">Rio de Janeiro</named-content><country country="BR">Brazil</country></aff><aff id="bjh13613-aff-0003"><label><sup>3</sup></label><named-content content-type="organisation-division">Centre for Biological Sciences</named-content><institution>University of Southampton</institution><named-content content-type="city">Southampton</named-content><country country="GB">UK</country></aff><aff id="bjh13613-aff-0004"><label><sup>4</sup></label><named-content content-type="organisation-division">Paediatric Malignancy Cytogenetics Unit</named-content><institution>Institute of Child Health &#x00026; Great Ormond Street Hospital</institution><named-content content-type="city">London</named-content><country country="GB">UK</country></aff><aff id="bjh13613-aff-0005"><label><sup>5</sup></label><named-content content-type="organisation-division">Department of Genetics</named-content><named-content content-type="organisation-division">Robert Debr&#x000e9; Hospital</named-content><institution>APHP</institution><named-content content-type="city">Paris</named-content><country country="FR">France</country></aff><aff id="bjh13613-aff-0006"><label><sup>6</sup></label><named-content content-type="organisation-division">Haematology Laboratory</named-content><named-content content-type="organisation-division">Saint&#x02010;Louis Louis Hospital</named-content><institution>APHP</institution><named-content content-type="city">Paris</named-content><country country="FR">France</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label>
Correspondence: Dr Anthony M. Ford and Dr Marcela B. Mansur, Centre for Evolution and Cancer, The Institute of Cancer Research (ICR) &#x02010; London, Brookes Lawley Building, 15 Cotswold Road, Sutton &#x02010; Surrey SM2 5NG, UK<break/>
E&#x02010;mails: <email>tony.ford@icr.ac.uk</email> and <email>mmansur@inca.gov.br</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>7</month><year>2015</year></pub-date><pub-date pub-type="ppub"><month>11</month><year>2015</year></pub-date><volume>171</volume><issue>4</issue><issue-id pub-id-type="doi">10.1111/bjh.2015.171.issue-4</issue-id><fpage>574</fpage><lpage>584</lpage><history><date date-type="received"><day>16</day><month>4</month><year>2015</year></date><date date-type="accepted"><day>25</day><month>6</month><year>2015</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2015 John Wiley & Sons Ltd. <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2015 The Authors. <italic>British Journal of Haematology</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:BJH-171-574.pdf"/><abstract id="bjh13613-abs-0001"><title>Summary</title><p>Infant T&#x02010;cell acute lymphoblastic leukaemia (<styled-content style="fixed-case">iT</styled-content>&#x02010;<styled-content style="fixed-case">ALL</styled-content>) is a very rare and poorly defined entity with a poor prognosis. We assembled a unique series of 13 infants with T&#x02010;<styled-content style="fixed-case">ALL</styled-content>, which allowed us to identify genotypic abnormalities and to investigate prenatal origins. Matched samples (diagnosis/remission) were analysed by single nucleotide polymorphism&#x02010;array to identify genomic losses and gains. In three cases, we identified a recurrent somatic deletion on chromosome 3. These losses result in the complete deletion of <italic><styled-content style="fixed-case">MLF</styled-content>1</italic> and have not previously been described in T&#x02010;<styled-content style="fixed-case">ALL</styled-content>. We observed two cases with an 11p13 deletion (<italic><styled-content style="fixed-case">LMO</styled-content>2</italic>&#x02010;related), one of which also harboured a deletion of <italic><styled-content style="fixed-case">RB</styled-content>1</italic>. Another case presented a large 11q14&#x000b7;1&#x02010;11q23&#x000b7;2 deletion that included <italic><styled-content style="fixed-case">ATM</styled-content></italic> and only five patients (38%) showed deletions of <italic><styled-content style="fixed-case">CDKN</styled-content>2A/B</italic>. Four cases showed <italic><styled-content style="fixed-case">NOTCH</styled-content>1</italic> mutations; in one case <italic><styled-content style="fixed-case">FBXW</styled-content>7</italic> was the sole mutation and three cases showed alterations in <italic><styled-content style="fixed-case">PTEN</styled-content></italic>. <italic><styled-content style="fixed-case">KMT</styled-content>2A</italic> rearrangements (<italic><styled-content style="fixed-case">KMT</styled-content>2A&#x02010;r</italic>) were detected in three out of 13 cases. For three patients, mutations and copy number alterations (including deletion of <italic><styled-content style="fixed-case">PTEN</styled-content></italic>) could be backtracked to birth using neonatal blood spot <styled-content style="fixed-case">DNA</styled-content>, demonstrating an <italic>in utero</italic> origin. Overall, our data indicates that <styled-content style="fixed-case">iT</styled-content>&#x02010;<styled-content style="fixed-case">ALL</styled-content> has a diverse but distinctive profile of genotypic abnormalities when compared to T&#x02010;<styled-content style="fixed-case">ALL</styled-content> in older children and adults.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="bjh13613-kwd-0001">infant</kwd><kwd id="bjh13613-kwd-0002">T&#x02010;cell acute lymphoblastic leukaemia</kwd><kwd id="bjh13613-kwd-0003">genomic profile</kwd><kwd id="bjh13613-kwd-0004"><styled-content style="fixed-case">CNA</styled-content>s and <italic>in utero</italic> origin</kwd></kwd-group><funding-group><award-group><funding-source>European Hematology Association</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Lady Tata Memorial Trust</funding-source></award-group></funding-group><funding-group><award-group><funding-source>INCA</funding-source></award-group></funding-group><funding-group><award-group><funding-source>CNPq</funding-source></award-group></funding-group><funding-group><award-group><funding-source>FAPERJ</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Kay Kendall Leukaemia Fund</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Leukaemia &#x00026; Lymphoma Research</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Institute of Cancer Research</funding-source></award-group></funding-group><counts><page-count count="11"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>bjh13613</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>November 2015</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.7.5 mode:remove_FC converted:26.01.2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Acute lymphoblastic leukaemia (ALL) in children is a diverse cancer characterized by associations between age at presentation, leukaemic subtype and recurrent genetic alterations (Pui <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0027" ref-type="ref">2004</xref>). ALL in infants is a rare subset often associated with <italic>KMT2A</italic> (also known as <italic>MLL</italic>) rearrangements (<italic>KMT2A&#x02010;r</italic>), a high leucocyte count at diagnosis, an immature or pro&#x02010;B&#x02010;cell lineage immunophenotype (CD10<sup>&#x02212;</sup>) and a prenatal origin <italic>in utero</italic> (Ford <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0012" ref-type="ref">1993</xref>; Biondi <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0003" ref-type="ref">2000</xref>). T&#x02010;ALL is prevalent in older children. Though there is molecular evidence that it can originate <italic>in utero</italic> (Ford <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0013" ref-type="ref">1997</xref>; Eguchi&#x02010;Ishimae <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0009" ref-type="ref">2008</xref>), it is a very rare disease in infants (Biondi <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0003" ref-type="ref">2000</xref>; Emerenciano <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0011" ref-type="ref">2013</xref>). In contrast to infant pro&#x02010;B&#x02010;lineage ALL with <italic>KMT2A&#x02010;AFF1</italic> fusion, in which an <italic>in utero</italic> origin has been clearly demonstrated (Ford <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0012" ref-type="ref">1993</xref>; Gale <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0014" ref-type="ref">1997</xref>), the developmental timing for T&#x02010;ALL is poorly defined.</p><p>In a previous study of T&#x02010;ALL, we evaluated fifteen cases in early childhood (age &#x02264;24&#x000a0;months) for mutations that are prevalent in infant ALL (pro&#x02010;B) or T&#x02010;ALL; <italic>NOTCH1</italic> mutations, although found less frequently than described for older T&#x02010;ALL paediatric cases, were the most frequent alterations among these younger patients, followed by the <italic>KMT2A&#x02010;r</italic> (Emerenciano <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0010" ref-type="ref">2006</xref>; Mansur <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0021" ref-type="ref">2010</xref>).</p><p>The availability of a unique series of 13 infant T&#x02010;ALL cases (iT&#x02010;ALL, &#x02264;12&#x000a0;months) along with 12 remission samples allowed us to determine the molecular profile of iT&#x02010;ALL [copy number alterations (CNAs)/gains and losses (loss of heterozygosity, LOH)] using high&#x02010;density Genome&#x02010;Wide single nucleotide polymorphism (SNP) array accompanied by next generation sequencing (NGS). We sought to investigate the possible prenatal onset of genetic abnormalities in iT&#x02010;ALL using a &#x02018;backtracking&#x02019; approach with neonatal blood spots (Guthrie cards).</p><sec id="bjh13613-sec-0002"><title>Materials and methods</title><sec id="bjh13613-sec-0003"><title>Patient samples</title><p>Seven Brazilian (BR1&#x02010;BR7), one English (UK1) and five French (FR1&#x02010;FR5) iT&#x02010;ALLs were included in this study (Supporting Information). Material from diagnostic bone marrow (BM) and/or peripheral blood (PB) was available from all patients and remission samples (non&#x02010;leukaemic) were collected for all but one patient (BR4, who did not achieve remission). Guthrie cards were obtained from four patients for use in our backtracking approach to trace prenatally acquired mutations.</p></sec><sec id="bjh13613-sec-0004"><title>Leukaemia characterization</title><p>In all cases, diagnosis of leukaemia was established by the morphology of lymphoid cells and immunophenotyping by flow cytometry using a previously established panel of monoclonal antibodies (Mansur <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0020" ref-type="ref">2009</xref>). The immunological classification of T&#x02010;ALL was performed according to the European Group for the Immunological Characterization of Leukaemias (EGIL) criteria (Bene <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0002" ref-type="ref">1995</xref>).</p></sec><sec id="bjh13613-sec-0005"><title>T&#x02010;ALL molecular screening</title><p>Diagnostic DNA samples from all iT&#x02010;ALL cases were analysed for the following gene abnormalities: <italic>NOTCH1</italic>,<italic> FBXW7</italic>,<italic> PTEN</italic>,<italic> IL7R</italic>,<italic> KRAS</italic>,<italic> NRAS</italic>,<italic> STIL&#x02010;TAL1&#x000a0;+&#x000a0;, TLX3&#x000a0;+&#x000a0;</italic> and <italic>KMT2A&#x02010;r</italic> (Weng <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0033" ref-type="ref">2004</xref>; Mansur <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0020" ref-type="ref">2009</xref>, <xref rid="bjh13613-bib-0022" ref-type="ref">2012</xref>; Zenatti <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0035" ref-type="ref">2011</xref>; Emerenciano <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0011" ref-type="ref">2013</xref>). T&#x02010;cell receptor gene rearrangements (<italic>TR&#x02010;r</italic>; gamma/<italic>TRG</italic>, delta/<italic>TRD</italic> and beta/<italic>TRB</italic>) were assessed using conditions recommended by the BIOMED&#x02010;2 Consortium (van Dongen <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0007" ref-type="ref">2003</xref>; Langerak <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0017" ref-type="ref">2012</xref>). Clonality was assessed by GeneScan<sup>&#x000ae;</sup> profiling (Applied Biosystems<sup>&#x000ae;</sup>, Waltham, MA, USA) followed by cloning of the products and Sanger sequencing. Sequences were analysed using the Ig BLAST (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/igblast/">www.ncbi.nlm.nih.gov/igblast/</ext-link>) and the ImMunoGeneTics database (<ext-link ext-link-type="uri" xlink:href="http://www.imgt.org">www.imgt.org</ext-link>).</p></sec><sec id="bjh13613-sec-0006"><title>Molecular analyses</title><p>Fluorescence <italic>in&#x000a0;situ</italic> hybridization (FISH), CNA analyses, NGS and backtracking of neonatal blood spots were all performed as described in Data&#x000a0;S1.</p></sec></sec><sec id="bjh13613-sec-0007"><title>Results</title><sec id="bjh13613-sec-0008"><title>Characterization of infant cases</title><p>Thirteen iT&#x02010;ALL cases were investigated. The median age at diagnosis was 9&#x000a0;months, there was no predominance of gender, and a high leucocyte count (&#x02265;50&#x000a0;&#x000d7;&#x000a0;10<sup>9</sup>/L) was observed in 12 out of 13 cases (Table&#x000a0;SI). Immunophenotype analyses performed on all 13 diagnostic cases revealed that six patients presented T&#x02010;IV profile, five cases T&#x02010;III and for the other two cases, one presented T&#x02010;I and the other a T&#x02010;II profile. The T&#x02010;I profile case (BR4) also expressed two classical myeloid markers CD13 and CD33 which, according to previously published criteria (Coustan&#x02010;Smith <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0005" ref-type="ref">2009</xref>), suggests an Early T&#x02010;cell Progenitor (ETP) leukaemia.</p></sec><sec id="bjh13613-sec-0009"><title>Molecular analysis</title><p>The main results from the targeted molecular analyses carried out on the iT&#x02010;ALL samples are shown in Table&#x000a0;<xref rid="bjh13613-tbl-0001" ref-type="table-wrap">1</xref>.</p><table-wrap id="bjh13613-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Clinical&#x02010;molecular characterization of infant T&#x02010;cell acute lymphoblastic leukaemia cases</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Patient ID</th><th align="left" valign="top" rowspan="1" colspan="1">Age (months)</th><th align="left" valign="top" rowspan="1" colspan="1">Gender</th><th align="left" valign="top" rowspan="1" colspan="1">EGIL</th><th align="left" valign="top" rowspan="1" colspan="1">TR&#x02010;r</th><th align="left" valign="top" rowspan="1" colspan="1">NOTCH1</th><th align="left" valign="top" rowspan="1" colspan="1">FBXW7</th><th align="left" valign="top" rowspan="1" colspan="1">PTEN</th><th align="left" valign="top" rowspan="1" colspan="1">IL7R</th><th align="left" valign="top" rowspan="1" colspan="1">KRAS/NRAS</th><th align="left" valign="top" rowspan="1" colspan="1">STIL&#x02010;TAL1</th><th align="left" valign="top" rowspan="1" colspan="1">KMT2A&#x02010;r</th><th align="left" valign="top" rowspan="1" colspan="1">Outcome</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<italic>BR1</italic>
</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">T&#x02010;IV</td><td align="left" rowspan="1" colspan="1">
<italic>TRG &#x00026; D</italic>
</td><td align="left" rowspan="1" colspan="1">HD Mut</td><td align="left" rowspan="1" colspan="1">Mut</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">Neg</td><td align="left" rowspan="1" colspan="1">Neg</td><td align="left" rowspan="1" colspan="1">Deceased</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>BR2</italic>
</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">T&#x02010;IV</td><td align="left" rowspan="1" colspan="1">
<italic>TRG, D &#x00026; B</italic>
</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">Neg</td><td align="left" rowspan="1" colspan="1">
<italic>MLLT1</italic>
</td><td align="left" rowspan="1" colspan="1">Deceased</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>BR3</italic>
</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">T&#x02010;IV</td><td align="left" rowspan="1" colspan="1">
<italic>TRG, D &#x00026; B</italic>
</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">Neg</td><td align="left" rowspan="1" colspan="1">Neg</td><td align="left" rowspan="1" colspan="1">Deceased</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>BR4</italic>
<xref ref-type="fn" rid="bjh13613-note-0002">a</xref>
</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">T&#x02010;I</td><td align="left" rowspan="1" colspan="1">No Rear</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">Neg</td><td align="left" rowspan="1" colspan="1">Neg</td><td align="left" rowspan="1" colspan="1">Deceased</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>BR5</italic>
<xref ref-type="fn" rid="bjh13613-note-0002">a</xref>
</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">T&#x02010;II</td><td align="left" rowspan="1" colspan="1">
<italic>TRG, D &#x00026; B</italic>
</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">Neg</td><td align="left" rowspan="1" colspan="1">Neg</td><td align="left" rowspan="1" colspan="1">Deceased</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>BR6</italic>
<xref ref-type="fn" rid="bjh13613-note-0002">a</xref>
</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">T&#x02010;III</td><td align="left" rowspan="1" colspan="1">
<italic>TRG, D &#x00026; B</italic>
</td><td align="left" rowspan="1" colspan="1">PEST Mut</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT/del</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">Neg</td><td align="left" rowspan="1" colspan="1">
<italic>MLLT1</italic>
</td><td align="left" rowspan="1" colspan="1">Alive/CCR</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>BR7</italic>
<xref ref-type="fn" rid="bjh13613-note-0002">a</xref>
</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">T&#x02010;III</td><td align="left" rowspan="1" colspan="1">
<italic>TRD</italic>
</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">Neg</td><td align="left" rowspan="1" colspan="1">Neg</td><td align="left" rowspan="1" colspan="1">Deceased</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>UK1</italic>
</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">T&#x02010;III</td><td align="left" rowspan="1" colspan="1">
<italic>TRG</italic>
</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">Neg</td><td align="left" rowspan="1" colspan="1">
<italic>MLLT4</italic>
</td><td align="left" rowspan="1" colspan="1">Deceased</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>FR1</italic>
</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">T&#x02010;III</td><td align="left" rowspan="1" colspan="1">
<italic>TRG &#x00026; D</italic>
</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">Mut</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">Neg</td><td align="left" rowspan="1" colspan="1">Neg</td><td align="left" rowspan="1" colspan="1">Alive/CCR</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>FR2</italic>
</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">T&#x02010;IV</td><td align="left" rowspan="1" colspan="1">
<italic>TRG, D &#x00026; B</italic>
</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">Neg</td><td align="left" rowspan="1" colspan="1">Neg</td><td align="left" rowspan="1" colspan="1">Deceased</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>FR3</italic>
</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">T&#x02010;III</td><td align="left" rowspan="1" colspan="1">
<italic>TRG &#x00026; D</italic>
</td><td align="left" rowspan="1" colspan="1">HD/PEST Mut</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">Mut</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">Neg</td><td align="left" rowspan="1" colspan="1">Neg</td><td align="left" rowspan="1" colspan="1">Deceased</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>FR4</italic>
</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">T&#x02010;IV</td><td align="left" rowspan="1" colspan="1">
<italic>TRG, D &#x00026; B</italic>
</td><td align="left" rowspan="1" colspan="1">HD Mut</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">Neg</td><td align="left" rowspan="1" colspan="1">Neg</td><td align="left" rowspan="1" colspan="1">Deceased</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>FR5</italic>
</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">T&#x02010;IV</td><td align="left" rowspan="1" colspan="1">
<italic>TRG &#x00026; D</italic>
</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">Mut</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">WT</td><td align="left" rowspan="1" colspan="1">Neg</td><td align="left" rowspan="1" colspan="1">Neg</td><td align="left" rowspan="1" colspan="1">Alive/CCR</td></tr></tbody></table><table-wrap-foot><fn id="bjh13613-note-0001"><p>ID, identification; EGIL, European Group for the Immunological Characterization of Leukaemias classification; <italic>TR&#x02010;r</italic>, T&#x02010;cell receptor rearrangements; Mut, mutated; WT, wild type; HD, Heterodimerization Domain; PEST, polypeptide enriched in proline, glutamic acid, serine and threonine domain; Neg, negative; Pos, positive; <italic>KMT2A&#x02010;r, KMT2A</italic> rearranged, <italic>KMT2A</italic> (also known as <italic>MLL</italic>); <italic>MLLT1</italic> (also known as <italic>ENL</italic>); <italic>MLLT4</italic> (also known as <italic>AF6</italic>); CCR, complete continuous remission. PEST and TAD (transactivation domain) are both designated as PEST domain only.</p></fn><fn id="bjh13613-note-0002"><label>a</label><p>Patients with available Guthrie cards (GC or neonatal blood spots).</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>The 13 diagnostic infant samples were screened for the known recurrent mutations in T&#x02010;ALL, including <italic>NOTCH1</italic>,<italic> FBXW7</italic>,<italic> PTEN</italic> and <italic>IL7R</italic> (detailed mutation data is shown in Table&#x000a0;SII), as well as <italic>KRAS</italic>,<italic> NRAS</italic> mutations, <italic>STIL&#x02010;TAL1</italic> fusion and the presence of <italic>TLX3</italic>. Results showed four cases were mutated for <italic>NOTCH1</italic>, two being mutated in the HD domain only (BR1 and FR4), one in the PEST only (BR6) and one (FR3) with mutations in both HD and PEST. Patient BR1 presented a combined <italic>NOTCH1/FBXW7</italic> mutation. One case (FR5) presented a sole <italic>FBXW7</italic> mutation. Three cases presented <italic>PTEN</italic> alterations (FR1 and FR3 as mutations and BR6 as CNA/deletion) and all patients were <italic>IL7R</italic>,<italic> KRAS</italic> and <italic>NRAS</italic> wild type (WT). <italic>KMT2A&#x02010;r</italic> was confirmed in three cases (two <italic>KMT2A&#x02010;MLLT1</italic> and one <italic>KMT2A&#x02010;MLLT4</italic>) and, distinct from childhood T&#x02010;ALL, we observed no infants with either <italic>STIL&#x02010;TAL1</italic>+ or <italic>TLX3</italic>+. <italic>TR&#x02010;r</italic> analyses were performed and all but one case (BR4) showed clonal rearrangements (Table&#x000a0;<xref rid="bjh13613-tbl-0001" ref-type="table-wrap">1</xref>).</p></sec><sec id="bjh13613-sec-0010"><title>SNP&#x02010;array and FISH data</title><p>All diagnostic samples were analysed by SNP&#x02010;array to identify genomic losses (LOH) and gains (Table&#x000a0;SIII), although one sample (BR1) had a low contrast quality control (CQC, Table&#x000a0;SIV). The DNA from this sample was extracted from diagnostic BM slides, from which we were able to identify two alterations: <italic>TR</italic> monoclonal rearrangements and <italic>CDKN2A</italic> homozygous deletion. Both results were confirmed using polymerase chain reaction (PCR) and quantitative PCR (Q&#x02010;PCR) approaches.</p><p>Among the CNAs identified by SNP&#x02010;array, we highlight genes considered as &#x02018;drivers&#x02019; of the leukaemic process i.e. those genes already causally implicated in the process of oncogenesis (Table&#x000a0;SIII). A recurrent 3q25&#x000b7;32 deletion was observed in three out of 13 cases (BR4, BR6 and BR7; Fig&#x000a0;<xref rid="bjh13613-fig-0001" ref-type="fig">1</xref>A) that encompassed <italic>MLF1</italic> (myeloid leukaemia factor 1), a negative regulator of cell cycle progression which functions upstream of the tumour suppressor <italic>TP53</italic> (Yoneda&#x02010;Kato <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0034" ref-type="ref">2005</xref>). For these 3 cases the deletion range varied between 528,000&#x000a0;bp and 610,000&#x000a0;bp but each deletion encompassed the entire <italic>MLF1</italic> gene. <italic>MLF1</italic> deletion was confirmed by FISH on case BR6, using a combination of <italic>MLF1</italic> and <italic>CDKN2A</italic> in&#x02010;house probes (Fig&#x000a0;<xref rid="bjh13613-fig-0001" ref-type="fig">1</xref>B). For the same patient, we also used FISH to confirm both <italic>KMT2A&#x02010;r</italic> and <italic>PTEN</italic> deletion (Fig&#x000a0;<xref rid="bjh13613-fig-0001" ref-type="fig">1</xref>B). Using a SP6&#x000b7;0&#x02010;array approach, we could not detect deletion of <italic>MLF1</italic> in over 90 European and Brazilian cases of childhood and adolescent T&#x02010;ALL (unpublished data).</p><fig fig-type="Figure" xml:lang="en" id="bjh13613-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Chromosome aberrations in infant T&#x02010;cell acute lymphoblastic leukaemia. (A) Copy number analysis of chromosome 3. The deleted region of chromosome 3 (<italic><styled-content style="fixed-case">MLF</styled-content>1</italic> included) is highlighted in grey for three of our patients (<styled-content style="fixed-case">BR</styled-content>4, <styled-content style="fixed-case">BR</styled-content>5 and <styled-content style="fixed-case">BR</styled-content>6); (B) <italic><styled-content style="fixed-case">MLF</styled-content>1</italic> (spectrum green) and <italic><styled-content style="fixed-case">CDKN</styled-content>2A</italic> (spectrum orange) in&#x02010;house probes confirming <italic><styled-content style="fixed-case">MLF</styled-content>1</italic> deletion in patient <styled-content style="fixed-case">BR</styled-content>6 &#x00026; <italic><styled-content style="fixed-case">KMT</styled-content>2A</italic> Break Apart (spectrum orange/spectrum green) and <italic><styled-content style="fixed-case">PTEN</styled-content></italic> (biotin&#x02010;Cy5/turquoise) probes showing <italic><styled-content style="fixed-case">KMT</styled-content>2A&#x02010;r</italic> and single copy of <italic><styled-content style="fixed-case">PTEN</styled-content></italic> in patient <styled-content style="fixed-case">BR</styled-content>6. (C) and (D) <styled-content style="fixed-case">SNP</styled-content>&#x02010;array and <styled-content style="fixed-case">FISH</styled-content> analysis of patient <styled-content style="fixed-case">UK</styled-content>1. (C) The grey boxes highlight the deleted areas in chromosomes 6 and 11, respectively; (D) <styled-content style="fixed-case">FISH</styled-content> using <styled-content style="fixed-case">LSI</styled-content>
<italic><styled-content style="fixed-case">MLL</styled-content></italic> (<italic><styled-content style="fixed-case">KMT</styled-content>2A</italic>) Dual Colour, Break Apart Rearrangement probe (spectrum orange/spectrum green) showing the <italic><styled-content style="fixed-case">KMT</styled-content>2A</italic> deletion (one orange signal missing); and in&#x02010;house probes, both designed in non&#x02010;deleted areas of <italic><styled-content style="fixed-case">MLLT</styled-content>4</italic>&#x02010;Cy3 and <italic><styled-content style="fixed-case">KMT</styled-content>2A</italic>&#x02010;spectrum green, confirming the <italic><styled-content style="fixed-case">KMT</styled-content>2A&#x02010;r</italic> between these two genes.</p></caption><graphic id="nlm-graphic-1" xlink:href="BJH-171-574-g001"/></fig><p>SNP&#x02010;array analyses also revealed one case (UK1) to harbour small deletions in <italic>KMT2A</italic> (11q23) and <italic>MLLT4</italic> genes (6q27) (Fig&#x000a0;<xref rid="bjh13613-fig-0001" ref-type="fig">1</xref>C) and, because <italic>MLLT4</italic> is recognized as a classical <italic>KMT2A</italic> translocation partner gene, we used FISH to search for a potential <italic>KMT2A&#x02010;r</italic>. Consequently, we first detected a <italic>KMT2A</italic> deletion using the LSI <italic>MLL (KMT2A)</italic> Dual Colour, Break Apart probe (Fig&#x000a0;<xref rid="bjh13613-fig-0001" ref-type="fig">1</xref>D) and then, using in&#x02010;house FISH probes for both <italic>KMT2A</italic> and <italic>MLLT4</italic>, we confirmed the occurrence of <italic>KMT2A&#x02010;r</italic> (Fig&#x000a0;<xref rid="bjh13613-fig-0001" ref-type="fig">1</xref>D).</p><p>In common with non&#x02010;infant paediatric T&#x02010;ALL, two of our infant cases revealed an 11p13del (BR3 and BR5; Fig&#x000a0;S1), a deletion first described in T&#x02010;ALL at a frequency of 4% that also involves region 11p12 (Van Vlierberghe <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0032" ref-type="ref">2006</xref>). Two other studies on childhood T&#x02010;ALL have identified the same deletion (Mullighan <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0025" ref-type="ref">2008</xref>; Szczepanski <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0030" ref-type="ref">2011</xref>). A large 11q14&#x02010;q23 deletion (Fig S1) including &#x02018;driver&#x02019; genes (<italic>ATM</italic>,<italic> EED</italic>) was observed in one case (FR4) while in another, (BR5), we observed a 13q14&#x000b7;2 deletion that involved the <italic>RB1</italic> gene (Fig&#x000a0;S2).</p><p>Further analysis of our iT&#x02010;ALL cohort revealed a lower frequency of <italic>CDKN2A</italic> deletions than found in paediatric T&#x02010;ALL. These deletions occur in 70% of T&#x02010;ALL (Mullighan <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0025" ref-type="ref">2008</xref>), but in our study only 38% of iT&#x02010;ALL cases harboured this deletion (Fig&#x000a0;<xref rid="bjh13613-fig-0002" ref-type="fig">2</xref>).</p><fig fig-type="Figure" xml:lang="en" id="bjh13613-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Genomic copy number analysis of <italic><styled-content style="fixed-case">CDKN</styled-content>2A</italic>. (A) <styled-content style="fixed-case">SNP</styled-content>&#x02010;array analysis of 9p21&#x000b7;3 for the 13 infant T&#x02010;cell acute lymphoblastic leukaemia patients, highlighting cases harbouring <italic><styled-content style="fixed-case">CDKN</styled-content>2A/B</italic> deletions (<styled-content style="fixed-case">BR</styled-content>1, <styled-content style="fixed-case">FR</styled-content>1, <styled-content style="fixed-case">FR</styled-content>2, <styled-content style="fixed-case">FR</styled-content>3 and <styled-content style="fixed-case">FR</styled-content>5), the deleted areas are shown in blue; and (B) and (C) Q&#x02010;<styled-content style="fixed-case">PCR</styled-content> copy number analysis with three different assays for <italic><styled-content style="fixed-case">CDKN</styled-content>2A</italic>. (B) The charts show patient <styled-content style="fixed-case">BR</styled-content>1 as homozygous deleted, also included in the analysis are one heterozygous control, two normal controls and <styled-content style="fixed-case">RPMI</styled-content>&#x02010;8402 (<italic><styled-content style="fixed-case">CDKN</styled-content>2A</italic> homozygous deleted). (C) Q&#x02010;<styled-content style="fixed-case">PCR</styled-content> copy number data for patient <styled-content style="fixed-case">UK</styled-content>1 and all French cases showing <italic><styled-content style="fixed-case">CDKN</styled-content>2A</italic> heterozygous deletion for patients <styled-content style="fixed-case">FR</styled-content>1, <styled-content style="fixed-case">FR</styled-content>2 and <styled-content style="fixed-case">FR</styled-content>5 and homozygous deletion for <styled-content style="fixed-case">FR</styled-content>3, <styled-content style="fixed-case">FR</styled-content>4 and <styled-content style="fixed-case">UK</styled-content>1 are both <italic><styled-content style="fixed-case">CDKN</styled-content>2A</italic> wild&#x02010;type (<styled-content style="fixed-case">WT</styled-content>).</p></caption><graphic id="nlm-graphic-3" xlink:href="BJH-171-574-g002"/></fig></sec><sec id="bjh13613-sec-0011"><title>Copy number assays &#x02013; Q&#x02010;PCR and promoter methylation status of CDKN2A</title><p>In order to confirm the <italic>CDKN2A</italic> SNP&#x02010;array data (Fig&#x000a0;<xref rid="bjh13613-fig-0002" ref-type="fig">2</xref>A) on the five patient samples showing 9p21&#x000b7;3 deletions, we performed real&#x02010;time Q&#x02010;PCR assays on all 13 diagnostic samples using three different copy number probes located across the gene. In Fig&#x000a0;<xref rid="bjh13613-fig-0002" ref-type="fig">2</xref>B we highlight in particular the SNP analysis for case BR1, for which the array data presented lower CQC compared with the other 12 cases. In this experiment, we used two normal control DNAs (2 <italic>CDKN2A</italic> copies), one heterozygous deleted control (1 <italic>CDKN2A</italic> copy) and DNA from the cell line RPMI&#x02010;8402 as a homozygous deleted control, (0 <italic>CDKN2A</italic> copies). Evaluation of the <italic>CDKN2A</italic> status in the other iT&#x02010;ALL cases is shown in Fig&#x000a0;<xref rid="bjh13613-fig-0002" ref-type="fig">2</xref>C and Fig&#x000a0;S3.</p><p>As the majority of our cases did not present a visible <italic>CDKN2A</italic> gene deletion, we explored a potential alternative pathway for <italic>CDKN2A</italic> inactivation, i.e. occurrence of <italic>CDKN2A</italic> promoter methylation. Accordingly, we performed methylation&#x02010;specific PCR on all 13 iT&#x02010;ALL patient samples and on two control cell lines: RAJI and HL60 (Supporting Information). Conventional Sanger sequencing of the PCR amplicons established the correct genomic location within the <italic>CDKN2A</italic> exon 1 CpG island and confirmed bisulfite modification of the unmethylated cytosine to uracil. As expected, the DNA from the RAJI cell line produced a strong band with methylated primers, while DNA from the HL60 cell line generated a strong band with unmethylated primers. None of the patients revealed a methylated profile for <italic>CDKN2A</italic> (Fig&#x000a0;S4), suggesting that methylation was not an alternative mode of <italic>CDKN2A</italic> inactivation in these cases.</p></sec><sec id="bjh13613-sec-0012"><title>NGS data</title><p>Due to the paucity of available DNA from most infants we were unable to perform NGS on all cases and consequently prioritized those cases for which Guthrie Cards were available.</p><p>Patient BR4 presented an ETP&#x02010;profile with no typical T&#x02010;ALL molecular alterations. We performed whole exome sequencing (WES) on DNA isolated from diagnostic material, however this patient did not achieve remission and therefore no germline material was available for matched analyses. In order to uncover somatic alterations acquired by&#x000a0;the leukaemic clone, we filtered out mutations listed in&#x000a0;the dbSNP and/or 1000genomes databases (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp/">http://www.ncbi.nlm.nih.gov/snp/</ext-link>; <ext-link ext-link-type="uri" xlink:href="http://www.1000genomes.org/">http://www.1000genomes.org/</ext-link>) and identified a total of 832 single nucleotide variations (SNVs) and 872 insertions or deletions (indels) at diagnosis.</p><p>In the BR4 diagnostic sample, after respectively filtering the data by read depth (between 20&#x02013;250x), coding areas only&#x000a0;and deleterious/possibly damaging at protein level (VEP&#x02010;Ensembl; <ext-link ext-link-type="uri" xlink:href="http://www.ensembl.org/Homo_sapiens/Tools/VEP">http://www.ensembl.org/Homo_sapiens/Tools/VEP</ext-link>), we detected 176 SNVs and 272 indels. We decided to focus&#x000a0;particularly on 22 affected genes, which have an established&#x000a0;causal role in oncogenesis and could therefore be considered as &#x02018;drivers&#x02019; of leukaemia. For SNVs we chose <italic>AIM1</italic>,<italic> SLC35D1</italic>,<italic> PIK3CB</italic>,<italic> DTHD1</italic>,<italic> TIE1</italic>,<italic> SH3BP2</italic>,<italic> MLLT4</italic>,<italic> MZF1</italic>,<italic> EP300</italic>,<italic> TLK2</italic>,<italic> NOL8</italic>,<italic> PIDD1</italic>,<italic> RPL3</italic>,<italic> TCTN2</italic> and <italic>CHFR</italic> and for indels we chose; <italic>KAT6B</italic>,<italic> TNK2, DLX6, BPTF</italic>,<italic> CNGB1</italic>,<italic> TUSC1</italic> and <italic>PDLIM5</italic> (Fig&#x000a0;<xref rid="bjh13613-fig-0003" ref-type="fig">3</xref>A and Table&#x000a0;SV). Due to the paucity of available patient material, we simply confirmed selected heterozygous point mutations and indels by Sanger sequencing in 14 out of the 22 chosen genes, i.e. <italic>AIM1</italic>,<italic> PIK3CB</italic>,<italic> DTHD1</italic>,<italic> TIE1</italic>,<italic> SH3BP2</italic>,<italic> MLLT4</italic>,<italic> MZF1</italic>,<italic> EP300</italic>,<italic> TLK2</italic>,<italic> PIDD1</italic>,<italic> RPL3</italic>,<italic> KAT6B</italic>,<italic> BPTF</italic> and <italic>PDLIM5</italic> (data not shown).</p><fig fig-type="Figure" xml:lang="en" id="bjh13613-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Principal mutations detected by next generation sequencing in patients <styled-content style="fixed-case">BR</styled-content>4 and <styled-content style="fixed-case">BR</styled-content>6. (A) List of the relevant genes affected by mutations (<styled-content style="fixed-case">SNV</styled-content>s and indels) for <styled-content style="fixed-case">BR</styled-content>4 at diagnosis. Guthrie card <styled-content style="fixed-case">DNA</styled-content>s (<styled-content style="fixed-case">GC</styled-content>) from patient <styled-content style="fixed-case">BR</styled-content>4 were not submitted to <styled-content style="fixed-case">WES</styled-content> analysis but were subsequently used to check the somatic <italic>versus</italic> germline status of the mutations detected at diagnosis. (B) Somatic alterations (<styled-content style="fixed-case">SNV</styled-content>s and indels) detected by <styled-content style="fixed-case">WGS</styled-content> in <styled-content style="fixed-case">BR</styled-content>6 diagnostic <styled-content style="fixed-case">DNA</styled-content>. A remission (germline) sample confirmed the somatic status of all the alterations listed. For both (A) and (B), we&#x000a0;highlight the mutations affecting coding areas only. Different colours discriminate <styled-content style="fixed-case">SNV</styled-content>s (<styled-content style="fixed-case">WES</styled-content>&#x02010;blue, <styled-content style="fixed-case">WGS</styled-content>&#x02010;green) from indels (<styled-content style="fixed-case">WES</styled-content>&#x02010;red, <styled-content style="fixed-case">WGS</styled-content>&#x02010;orange). **<styled-content style="fixed-case">WES</styled-content> was not performed on this material. Guthrie card <styled-content style="fixed-case">DNA</styled-content>s were investigated by conventional Sanger sequencing. SNV, single nucleotide variation; indel, insertion or deletion; WES, whole exome sequencing; WGS, whole genome sequencing; WT, wild&#x02010;type.</p></caption><graphic id="nlm-graphic-5" xlink:href="BJH-171-574-g003"/></fig><p>For patient BR6 we used a whole genome sequencing (WGS) approach to precisely determine the CNAs breakpoints with the aim of using this data for subsequent blood spot backtracking analyses. We filtered the WGS data by somatic alterations only, somatic <italic>P&#x000a0;</italic>&#x02264;&#x000a0;0&#x000b7;05 and exonic areas only and identified 145 mutations (SNVs and indels). Here, we particularly highlight 15 genes that were affected by novel mutations, i.e. mutations not been previously described in reference databases. The genes were: <italic>CCDC162P</italic>,<italic> ADAMTS7</italic>,<italic> IGSF3</italic>,<italic> LOC100506990</italic>,<italic> SPATA31C2</italic>,<italic> NOS2</italic>,<italic> ANKRD20A5P</italic>,<italic> HNRNPCL1</italic>,<italic> TMEM51&#x02010;AS1</italic>,<italic> LOC388692</italic>,<italic> KCTD18</italic>,<italic> LOC100506060</italic>,<italic> MLLT10P1</italic>,<italic> OLIG1</italic> and <italic>NOTCH1</italic> (Fig&#x000a0;<xref rid="bjh13613-fig-0003" ref-type="fig">3</xref>B and Table&#x000a0;SVI). Table&#x000a0;<xref rid="bjh13613-tbl-0002" ref-type="table-wrap">2</xref> summarises the main genomic abnormalities observed in our rare series of iT&#x02010;ALL.</p><table-wrap id="bjh13613-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Main genomic findings observed in our series of infant T&#x02010;cell acute lymphoblastic leukaemia cases</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Patient ID</th><th align="left" valign="top" rowspan="1" colspan="1">Main CNAs</th><th align="left" valign="top" rowspan="1" colspan="1">Gene Alterations</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">BR1</td><td align="left" rowspan="1" colspan="1">
<italic>CDKN2A/B</italic> del</td><td align="left" rowspan="1" colspan="1">
<italic>NOTCH1</italic> and <italic>FBXW7</italic> mutations</td></tr><tr><td align="left" rowspan="3" colspan="1">BR2</td><td align="left" rowspan="1" colspan="1">
<italic>IKZF1</italic> del</td><td align="left" rowspan="3" colspan="1">
<italic>KMT2A&#x02010;MLLT1</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>ETV6</italic> del</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>FLT3</italic> del</td></tr><tr><td align="left" rowspan="1" colspan="1">BR3</td><td align="left" rowspan="1" colspan="1">
<italic>11p13del/LMO2</italic> over</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="4" colspan="1">BR4</td><td align="left" rowspan="4" colspan="1">
<italic>MLF1</italic> del</td><td align="left" rowspan="1" colspan="1">
<italic>AIM1, SLC35D1, PIK3CB, DTHD1, TIE1,</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>SH3BP2, MLLT4, MZF1, EP300, TLK2,</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>NOL8, PIDD1, RPL3, TCTN2, CHFR, KAT6B,</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>TNK2, DLX6, BPTF, CNGB1, TUSC1</italic> and <italic>PDLIM5</italic>
</td></tr><tr><td align="left" rowspan="2" colspan="1">BR5</td><td align="left" rowspan="1" colspan="1">
<italic>11p13del/LMO2</italic> over</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>RB1</italic> del</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">BR6</td><td align="left" rowspan="1" colspan="1">
<italic>MLF1</italic> del</td><td align="left" rowspan="1" colspan="1">
<italic>KMT2A&#x02010;MLLT1</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>PTEN</italic> del</td><td align="left" rowspan="1" colspan="1">
<italic>NOTCH1</italic> mutation</td></tr><tr><td align="left" rowspan="1" colspan="1">BR7</td><td align="left" rowspan="1" colspan="1">
<italic>MLF1</italic> del</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">UK1</td><td align="left" rowspan="1" colspan="1">
<italic>MLLT4</italic> del</td><td align="left" rowspan="2" colspan="1">
<italic>KMT2A&#x02010;MLLT4</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>KMT2A</italic> del</td></tr><tr><td align="left" rowspan="1" colspan="1">FR1</td><td align="left" rowspan="1" colspan="1">
<italic>CDKN2A/B</italic> del</td><td align="left" rowspan="1" colspan="1">
<italic>PTEN</italic> mutation</td></tr><tr><td align="left" rowspan="1" colspan="1">FR2</td><td align="left" rowspan="1" colspan="1">
<italic>CDKN2A/B</italic> del</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">FR3</td><td align="left" rowspan="1" colspan="1">
<italic>CDKN2A/B</italic> del</td><td align="left" rowspan="1" colspan="1">
<italic>NOTCH1</italic> and <italic>PTEN</italic> mutations</td></tr><tr><td align="left" rowspan="1" colspan="1">FR4</td><td align="left" rowspan="1" colspan="1">
<italic>11q14&#x02010;q23del/ATM</italic> and <italic>EED</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>NOTCH1</italic> mutation</td></tr><tr><td align="left" rowspan="1" colspan="1">FR5</td><td align="left" rowspan="1" colspan="1">
<italic>CDKN2A/B</italic> del</td><td align="left" rowspan="1" colspan="1">
<italic>FBXW7</italic> mutation</td></tr></tbody></table><table-wrap-foot><fn id="bjh13613-note-0003"><p>ID, identification; CNAs, copy number alterations; del, deletion; over, overexpression.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="bjh13613-sec-0013"><title>Backtracking aberrations to an origin in utero</title><p>We also sought to investigate the early onset of genetic abnormalities by backtracking to birth the aberrations already present at diagnosis. We obtained archived Guthrie cards of four of the patients (BR4, BR5, BR6 and BR7). Potential clonal markers among these four patients included: a rearranged <italic>TRD</italic> (BR7); a <italic>KMT2A&#x02010;r,</italic> a <italic>PTEN</italic> deletion and a <italic>NOTCH1</italic> indel (all in BR6); and 11p13 and <italic>RB1</italic> deletions (both in BR5). The fourth case (BR4) harboured 22 mutations affecting cancer&#x02010;associated genes and a <italic>MLF1</italic> deletion as its only CNA.</p><p>We previously determined <italic>MLLT1</italic> as the partner for <italic>KMT2A&#x02010;r</italic> in patient BR6 and subsequently the breakpoint sequence of this rearrangement (Emerenciano <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0011" ref-type="ref">2013</xref>), which allowed us to design patient&#x02010;specific primers to interrogate this rearrangement in the Guthrie card DNAs. From ten individual Guthrie card DNAs examined for BR6, one was <italic>KMT2A&#x02010;MLLT1</italic>
<sup><italic>+</italic></sup> (Fig&#x000a0;<xref rid="bjh13613-fig-0004" ref-type="fig">4</xref>A). To investigate the prenatal origin of the <italic>NOTCH1</italic> indel detected at diagnosis we also performed a specific semi&#x02010;nested PCR experiment. In total, we analysed 1200 cloned sequences from the ten blood spot DNAs and identified a single clone with the same <italic>NOTCH1</italic>&#x02010;PEST deletion that was present at diagnosis (c.7280delG). Unexpectedly, this clone also harboured a new mutation found 36 base pairs upstream from c.7280delG, (i.e. c.7244_7246delCAC, Fig&#x000a0;<xref rid="bjh13613-fig-0004" ref-type="fig">4</xref>B). This 3 base&#x02010;pair CAC deletion was also detected alone in 15/1200 Guthrie card clones. Although this deletion was not initially discovered in the&#x000a0;bulk DNA analysis of diagnostic material, after cloning the <italic>NOTCH1</italic>&#x02010;PEST amplicon from BR6 diagnostic DNA, we found 1/100 clones with both c.7244_7246delCAC and c.7280delG (Fig&#x000a0;<xref rid="bjh13613-fig-0004" ref-type="fig">4</xref>B). Furthermore, as expected for a heterozygous mutation, we observed 50/100 clone sequences with the c.7280delG only. These results suggest that <italic>NOTCH1</italic> c.7280delG and c.7244_7246delCAC both occurred prenatally and that the latter potentially occurred (independently) in a cell that did not represent the major clone at diagnosis.</p><fig fig-type="Figure" xml:lang="en" id="bjh13613-fig-0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Prenatally acquired alterations in patient <styled-content style="fixed-case">BR</styled-content>6. (A) <italic><styled-content style="fixed-case">KMT</styled-content>2A&#x02010;<styled-content style="fixed-case">MLLT</styled-content>1</italic> Sanger sequencing of <styled-content style="fixed-case">BR</styled-content>6 diagnostic and Guthrie card <styled-content style="fixed-case">DNA</styled-content>s, showing that the patient presented an identical <italic><styled-content style="fixed-case">KMT</styled-content>2A&#x02010;<styled-content style="fixed-case">MLLT</styled-content>1</italic> breakpoint at both time points. Top panel: <styled-content style="fixed-case">GRC</styled-content>h38 Primary Assembly as reference for both gene sequences (<italic><styled-content style="fixed-case">KMT</styled-content>2A</italic>/<styled-content style="fixed-case">NC</styled-content>_000011&#x000b7;10 and <italic><styled-content style="fixed-case">MLLT</styled-content>1</italic>/<styled-content style="fixed-case">NC</styled-content>_000019&#x000b7;10). M&#x02010;H&#x000a0;=&#x000a0;micro&#x02010;homologies. (B) Cloning experiment detecting <italic><styled-content style="fixed-case">NOTCH</styled-content>1</italic>&#x02010;<styled-content style="fixed-case">PEST</styled-content> deletion in the Guthrie card. The top sequence shows the <italic><styled-content style="fixed-case">NOTCH</styled-content>1</italic>
<styled-content style="fixed-case">NCBI</styled-content> Reference Sequence &#x02013; <styled-content style="fixed-case">NM</styled-content>_017617&#x000b7;3 &#x02013; used to locate both mutations. The base pairs and amino acids deleted are highlighted in the red boxes. The first box represents sequenced Guthrie card <styled-content style="fixed-case">DNA</styled-content> (colony 27) from patient <styled-content style="fixed-case">BR</styled-content>6 harbouring both <italic><styled-content style="fixed-case">NOTCH</styled-content>1</italic>&#x02010;<styled-content style="fixed-case">PEST</styled-content> deletions, i.e. c.7244_7246del<styled-content style="fixed-case">CAC</styled-content> and c.7280delG and the second box shows <styled-content style="fixed-case">BR</styled-content>6 diagnostic <styled-content style="fixed-case">DNA</styled-content> (colony 61) also presenting both deletions. The c.7244_7246del<styled-content style="fixed-case">CAC</styled-content> causes a Proline (P) deletion (# in the protein sequence p.2415delP), whereas c.7280delG generates a premature stop codon (*). <bold>(C)</bold>
<italic><styled-content style="fixed-case">PTEN</styled-content></italic> deletion breakpoint in patient <styled-content style="fixed-case">BR</styled-content>6 diagnostic and Guthrie card <styled-content style="fixed-case">DNA</styled-content>s. Primers 1 and 3 were used for the first <styled-content style="fixed-case">PCR</styled-content> reaction and 2 and 3 for the semi&#x02010;nested one. Sanger sequencing data shows the deletion breakpoint present in both diagnostic (top, <styled-content style="fixed-case">BR</styled-content>6 Diagnostic <styled-content style="fixed-case">DNA</styled-content>) and also in one of ten Guthrie card <styled-content style="fixed-case">DNA</styled-content>s tested (bottom, <styled-content style="fixed-case">BR</styled-content>6 Guthrie card <styled-content style="fixed-case">DNA</styled-content>&#x02010;<styled-content style="fixed-case">GC</styled-content>5). <styled-content style="fixed-case">GRC</styled-content>h37/hg19 was the reference for these analyses.</p></caption><graphic id="nlm-graphic-7" xlink:href="BJH-171-574-g004"/></fig><p>We used WGS to determine the precise breakpoint for the <italic>PTEN</italic> deletion detected by SNP&#x02010;array in the BR6 diagnostic sample. The breakpoint in this diagnostic material was cloned using specific primers designed from the WGS coordinates (Fig&#x000a0;<xref rid="bjh13613-fig-0004" ref-type="fig">4</xref>C). Subsequently, we used a semi&#x02010;nested approach to interrogate the ten DNAs from the Guthrie cards of this patient. One positive DNA (GC5) was identified and Sanger sequenced, confirming that the <italic>PTEN</italic> deletion in the diagnostic sample was present at birth (Fig&#x000a0;<xref rid="bjh13613-fig-0004" ref-type="fig">4</xref>C). To our knowledge this is the first observation of a gene deletion being identified in a neonatal blood spot.</p><p>We next tested the blood spot DNAs from patient BR4 by conventional PCR for the 14 WES mutations validated in the diagnostic DNA. Unfortunately, this patient did not achieve remission and died shortly after diagnosis. All 14 mutations were found in the four Guthrie card DNAs tested (Fig&#x000a0;<xref rid="bjh13613-fig-0004" ref-type="fig">4</xref>A), thus confirming their presence before birth. Nevertheless, we cannot confirm whether these were acquired as somatic mutations <italic>in utero</italic> solely in haematopoietic cells or were indeed germline mutations.</p><p>For patient BR5 we were unable to clone the deletion breakpoints for 11p13 (Fig&#x000a0;S1) or for a large heterozygous deletion on chromosome 13 downstream of exon 1 in the tumour suppressor gene <italic>RB1</italic> (Fig&#x000a0;S2A). However, using Q&#x02010;PCR copy number analysis (Figs&#x000a0;S2B and C) we were able to detect the loss of intron 17 of <italic>RB1</italic> in diagnostic and BR5 Guthrie card DNA while intron 1 was undeleted in both. The heterozygous deletion was variably detected in all Guthrie DNAs tested, but not in remission DNA, again suggesting a potential <italic>in utero</italic> origin for this aberration.</p><p>Finally, the <italic>TRD</italic> rearrangement identified in patient BR7 contained a very small V(N)J junction which, although found to be present in its neonatal blood spot, could not be confirmed as being patient&#x02010;specific with adequate specificity.</p></sec></sec><sec id="bjh13613-sec-0014"><title>Discussion</title><p>A novel finding in this unique series of iT&#x02010;ALL was the loss of 3q25&#x000b7;32 resulting in the complete deletion of <italic>MLF1</italic>, not previously described in T&#x02010;ALL nor in acute leukaemias as a deletion. In addition, we have interrogated over 90 European and Brazilian cases of childhood and adolescent T&#x02010;ALL and we were not able to detect this deletion (unpublished data). These data support the notion that deletion of <italic>MLF1</italic> may represent a specific marker of iT&#x02010;ALL. This gene was originally identified as a partner of <italic>NPM1</italic> in the translocation t(3;5)(q25;q34), commonly found in acute myeloid leukaemia (AML) and myelodysplastic syndromes and has been shown to play a key role in the leukaemogenesis of these neoplasias (Bras <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0004" ref-type="ref">2012</xref>). <italic>MLF1</italic> plays a regulatory role in TP53 activity, stabilizing the protein by suppressing its E3 ubiquitin ligase (<italic>RFWD2</italic>) (Yoneda&#x02010;Kato <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0034" ref-type="ref">2005</xref>). Based on these findings we suggest that this gene deletion may have an oncogenic function because TP53 degradation is triggered by E3 ubiquitin ligase activity in the absence of <italic>MLF1</italic>. Hence, we hypothesize that <italic>MLF1</italic> could act as a recurrent tumour suppressor gene in iT&#x02010;ALL, however functional studies will be needed to elucidate its role in leukaemogenesis.</p><p>We provide evidence that iT&#x02010;ALL, in common with infant pro&#x02010;B ALL (Ford <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0012" ref-type="ref">1993</xref>; Gale <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0014" ref-type="ref">1997</xref>) and at least some cases of T&#x02010;ALL in childhood (Ford <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0013" ref-type="ref">1997</xref>; Eguchi&#x02010;Ishimae <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0009" ref-type="ref">2008</xref>), can be initiated <italic>in utero</italic>. Definitive data was obtained on one patient (BR6). The neonatal blood spots archived for BR6 harboured the clonotypic <italic>KMT2A&#x02010;MLLT1</italic> fusion sequence, as well as the <italic>NOTCH1</italic> mutation and the <italic>PTEN</italic> deletion, albeit at low frequencies. Additionally, we found evidence suggesting independent deletions in the PEST domain of <italic>NOTCH1</italic>. Given the very young age of the patient this is not surprising, nevertheless these data suggest not only a prenatal initiation of iT&#x02010;ALL but significant clonal evolution prior to birth, i.e. sequential acquisition of several mutations. This might help explain the presentation features of high white cell count but very young age (BR6, 7&#x000a0;months). In contrast, for children who present with <italic>ETV6&#x02010;RUNX1</italic> pre&#x02010;B ALL at an older age, usually with low or modest leukaemic burdens, the fusion gene appears to be the only prenatal &#x02018;driver&#x02019; event (Ma <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0019" ref-type="ref">2013</xref>).</p><p>Our series of iT&#x02010;ALL displayed a lower frequency of all the major recurrent gene alterations and CNAs found in childhood T&#x02010;ALL (Mullighan <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0024" ref-type="ref">2007</xref>; Andersson <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0001" ref-type="ref">2015</xref>). <italic>PTEN</italic> mutations and/or deletions appeared to be the only abnormality that occurred with the expected frequency (9&#x02010;20%) (Gutierrez <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0015" ref-type="ref">2009</xref>; Mendes <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0023" ref-type="ref">2014</xref>). We also observed a lower frequency of alterations affecting <italic>CDKN2A</italic> than has been found in childhood leukaemia, suggesting that its role in iT&#x02010;ALL leukaemogenesis may be less important than in childhood T&#x02010;ALL or B lineage ALL (Mullighan <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0024" ref-type="ref">2007</xref>). An absence of CNAs was recently reported in <italic>KMT2A&#x02010;r</italic> infant ALL (Andersson <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0001" ref-type="ref">2015</xref>).</p><p>Previous literature reported a single case with concomitant <italic>KMT2A</italic> deletion and <italic>KMT2A&#x02010;MLLT4</italic> rearrangement, these abnormalities both being present in the diagnostic sample of a three&#x02010;year&#x02010;old child with T&#x02010;ALL (De Braekeleer <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0006" ref-type="ref">2010</xref>). Therefore, patient UK1 is the second reported T&#x02010;ALL case with these <italic>KMT2A</italic> alterations combined. Deletion of <italic>KMT2A</italic> has also been described in cases of precursor B infant ALL with <italic>KMT2A&#x02010;r</italic> (Andersson <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0001" ref-type="ref">2015</xref>).</p><p>A deletion in the classical tumour suppressor gene, <italic>RB1</italic>, was observed in one (BR5) of our 13 cases. <italic>RB1</italic> deletions are described at a frequency of 6&#x02010;10% for both B&#x02010;cell precursor ALL and T&#x02010;ALL in children and adults (Okamoto <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0026" ref-type="ref">2010</xref>; Schwab <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0028" ref-type="ref">2013</xref>). Deletion at 11p12p13 can act to transcriptionally activate the <italic>LMO2</italic> gene, a classic oncogene in T&#x02010;cell leukaemogenesis (Lecuyer &#x00026; Hoang, <xref rid="bjh13613-bib-0018" ref-type="ref">2004</xref>). Deletions affecting locus 11p13 were identified in two of our cases, including BR5, suggesting that this deletion could lead to <italic>LMO2</italic> activation and contribute to the development of iT&#x02010;ALL. Unfortunately, cells were not available from these patients to investigate <italic>LMO2</italic> expression. The 11q14&#x000b7;1&#x02010;q23&#x000b7;2del Chr11q/<italic>ATM</italic> deletions present in patient FR4 have been reported in 30% of chronic lymphocytic leukaemia cases (Edelmann <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0008" ref-type="ref">2012</xref>; Skowronska <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0029" ref-type="ref">2012</xref>) and at a lower rate in ALL (Schwab <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0028" ref-type="ref">2013</xref>).</p><p>Patient BR4 presented an ETP&#x02010;profile with no typical T&#x02010;ALL molecular alterations. Hence, we performed WES analyses with a view to uncovering potential &#x02018;driver&#x02019; alterations that could account for the emergence of leukaemia. By grouping our 22 highlighted genes according to the hallmarks of cancer (Hanahan &#x00026; Weinberg, <xref rid="bjh13613-bib-0016" ref-type="ref">2011</xref>), we uncovered roles including sustaining proliferative signalling, activating invasion and metastasis, resisting cell death and evading growth suppressors. Furthermore, three groups of mutations characteristic of ETP&#x02010;ALL (RAS signalling, haematopoietic and epigenetic regulators) (Zhang <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0036" ref-type="ref">2012</xref>) were also observed in our case. Some of the aberrant genes that we uncovered do not yet have their functions fully elucidated. Given the ease of detection of mutations in the neonatal blood spots of this patient, compared to our other cases, we speculate that they may be germline mutations. It is of interest that an excess of germline variations in <italic>KMT2A&#x02010;r</italic> negative infant leukaemia has been described by Valentine <italic>et&#x000a0;al</italic> (<xref rid="bjh13613-bib-0031" ref-type="ref">2014</xref>), who suggested that such cases may well be enriched for rare coding and deleterious germline variations in cancer&#x02010;associated genes. The authors postulate that such variations might comprise some proportion of the expected functional imbalance characteristically observed in cancer. This notion aligns with our own <italic>KMT2A&#x02010;r</italic> negative case that also did not reveal any of the expected ETP somatic mutations, such as <italic>SETD2</italic> or <italic>EZH2</italic>. Nevertheless <italic>EP300,</italic> a known &#x02018;driver&#x02019; for ETP&#x02010;ALL (Zhang <italic>et&#x000a0;al</italic>, <xref rid="bjh13613-bib-0036" ref-type="ref">2012</xref>), was carried as a suspected germline mutation in patient BR4.</p><p>In summary, we have analysed the genomic abnormalities in a unique series of a rare subtype of paediatric leukaemia &#x02013; T&#x02010;ALL in infants. The genotypes or mutational spectra are varied but, overall, different from those of T&#x02010;ALL in older children and adults. A novel aberration (for acute leukaemia), <italic>MLF1</italic> deletion, was present as a recurrent abnormality in three of 13 cases. Finally, we have provided evidence that some of the genetic abnormalities, including a <italic>PTEN</italic> deletion, were accrued prenatally.</p></sec><sec id="bjh13613-sec-0016"><title>Author contributions</title><p>MBM: designed the study, conducted and analysed all the experiments and wrote the paper; FWvD: supervised all SNP procedures and analyses; SMC: assisted in sample preparation and supervised the FISH experiments; CLF and ME: performed FISH and/or molecular investigations; HK, EC, HC, JS: provided clinical samples and immunophenotypic/cytogenetic/clinical data; JG: performed the WGS analyses; MSPO and MG: designed the study and wrote the paper; AMF: designed and supervised the study, generated and analysed experimental data and wrote the paper. All authors critically reviewed and approved the final draft of the manuscript.</p></sec><sec id="bjh13613-sec-0017"><title>Conflict of interest</title><p>The authors declare no conflict of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data"><caption><p>
<bold>Data S1.</bold> Materials and methods.</p><p>
<bold>Data S2.</bold> Supplementary tables with additional data.</p></caption><media xlink:href="BJH-171-574-s001.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data"><caption><p>
<bold>Fig S1.</bold> Copy number analysis of chromosome 11 in our iT&#x02010;ALL series.</p></caption><media xlink:href="BJH-171-574-s002.ppt"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data"><caption><p>
<bold>Fig S2.</bold> Genomic copy number analysis of <italic>RB1</italic>.</p></caption><media xlink:href="BJH-171-574-s003.ppt"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data"><caption><p>
<bold>Fig S3.</bold>
<italic>CDKN2A</italic> Q&#x02010;PCR copy number data of the Brazilian patients.</p></caption><media xlink:href="BJH-171-574-s004.ppt"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data"><caption><p>
<bold>Fig S4.</bold> Methylation specific PCR (MSP) in our iT&#x02010;ALL cohort and two control cell lines.</p></caption><media xlink:href="BJH-171-574-s005.ppt"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data"><caption><p>
<bold>Table&#x000a0;SI.</bold> Clinical&#x02013;demographic data of infant T&#x02010;ALL cases.</p></caption><media xlink:href="BJH-171-574-s006.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data"><caption><p>
<bold>Table&#x000a0;SII.</bold> Mutation screening data of infant T&#x02010;ALL cases.</p></caption><media xlink:href="BJH-171-574-s007.xls"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data"><caption><p>
<bold>Table&#x000a0;SIII.</bold> SNP&#x02010;array copy number data of infant T&#x02010;ALL cases.</p></caption><media xlink:href="BJH-171-574-s008.xls"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data"><caption><p>
<bold>Table&#x000a0;SIV.</bold> Contrast quality control (QC) data from SNP6&#x000b7;0&#x02010;arrays of the infant T&#x02010;ALL cases.</p></caption><media xlink:href="BJH-171-574-s009.xls"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data"><caption><p>
<bold>Table&#x000a0;SV.</bold> WES data details for patient BR4.</p></caption><media xlink:href="BJH-171-574-s010.xls"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data"><caption><p>
<bold>Table&#x000a0;SVI.</bold> WGS data details for patient BR6.</p></caption><media xlink:href="BJH-171-574-s011.xls"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="bjh13613-sec-0015"><title>Acknowledgements</title><p>The authors would like to thank patients and families that agreed to be involved in the study. Our thanks to the Brazilian Collaborative Study Group of Infant Acute Leukaemia, especially Dr. Terezinha Marques Salles, Dr. Teresa Cristina Cardoso Fonseca, Dr. Isis Quesado Magalh&#x000e3;es, Dr. Anna Carolina Dias, Dr. Imaru&#x000ed; Costa, Dr. Jane de Almeida Dobbin and Dr. Renato de Paula Guedes Oliveira for providing patient samples. The authors also acknowledge staff and services provided by INCA and ICR. This research was funded by the Partner Fellowship (#2011/01) awarded to MBM by the European Hematology Association; by the International Award for Research in Leukaemia awarded to MBM by the Lady Tata Memorial Trust; INCA, CNPq and FAPERJ (MSPO); the Kay Kendall Leukaemia Fund (FWvD); the Leukaemia &#x00026; Lymphoma Research (AMF, CLF and MG) and The Institute of Cancer Research (AMF and SMC). MBM has also been granted a partial scholarship from INCA.</p></ack><ref-list content-type="cited-references" id="bjh13613-bibl-0001"><title>References</title><ref id="bjh13613-bib-0001"><mixed-citation publication-type="journal" id="bjh13613-cit-0001">
<string-name>
<surname>Andersson</surname>, <given-names>A.K.</given-names>
</string-name>, <string-name>
<surname>Ma</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Gedman</surname>, <given-names>A.L.</given-names>
</string-name>, <string-name>
<surname>Dang</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Nakitandwe</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Holmfeldt</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Parker</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Easton</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Huether</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Kriwacki</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Rusch</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Wu</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Mulder</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Raimondi</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Pounds</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Kang</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Shi</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Becksfort</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Gupta</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Payne&#x02010;Turner</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Vadodaria</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Boggs</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Yergeau</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Manne</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Song</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Edmonson</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Nagahawatte</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Wei</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Pei</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Sutton</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Venn</surname>, <given-names>N.C.</given-names>
</string-name>, <string-name>
<surname>Chetcuti</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Rush</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Catchpoole</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Heldrup</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Fioretos</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Lu</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Ding</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Pui</surname>, <given-names>C.H.</given-names>
</string-name>, <string-name>
<surname>Shurtleff</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Mullighan</surname>, <given-names>C.G.</given-names>
</string-name>, <string-name>
<surname>Mardis</surname>, <given-names>E.R.</given-names>
</string-name>, <string-name>
<surname>Wilson</surname>, <given-names>R.K.</given-names>
</string-name>, <string-name>
<surname>Gruber</surname>, <given-names>T.A.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>, <given-names>J.</given-names>
</string-name> &#x00026; <string-name>
<surname>Downing</surname>, <given-names>J.R.</given-names>
</string-name> &#x00026; <collab collab-type="authors">St. Jude Children's Research Hospital&#x02010;Washington University Pediatric Cancer Genome Project</collab>
. (<year>2015</year>) <article-title>The landscape of somatic mutations in infant MLL&#x02010;rearranged acute lymphoblastic leukemias</article-title>. <source>Nature Genetics</source>, <volume>47</volume>, <fpage>330</fpage>&#x02013;<lpage>337</lpage>.<pub-id pub-id-type="pmid">25730765</pub-id></mixed-citation></ref><ref id="bjh13613-bib-0002"><mixed-citation publication-type="journal" id="bjh13613-cit-0002">
<string-name>
<surname>Bene</surname>, <given-names>M.C.</given-names>
</string-name>, <string-name>
<surname>Castoldi</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Knapp</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Ludwig</surname>, <given-names>W.D.</given-names>
</string-name>, <string-name>
<surname>Matutes</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Orfao</surname>, <given-names>A.</given-names>
</string-name> &#x00026; <string-name>
<surname>van't Veer</surname>, <given-names>M.B.</given-names>
</string-name> (<year>1995</year>) <article-title>Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL)</article-title>. <source>Leukemia</source>, <volume>9</volume>, <fpage>1783</fpage>&#x02013;<lpage>1786</lpage>.<pub-id pub-id-type="pmid">7564526</pub-id></mixed-citation></ref><ref id="bjh13613-bib-0003"><mixed-citation publication-type="journal" id="bjh13613-cit-0003">
<string-name>
<surname>Biondi</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Cimino</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Pieters</surname>, <given-names>R.</given-names>
</string-name> &#x00026; <string-name>
<surname>Pui</surname>, <given-names>C.H.</given-names>
</string-name> (<year>2000</year>) <article-title>Biological and therapeutic aspects of infant leukemia</article-title>. <source>Blood</source>, <volume>96</volume>, <fpage>24</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">10891426</pub-id></mixed-citation></ref><ref id="bjh13613-bib-0004"><mixed-citation publication-type="journal" id="bjh13613-cit-0004">
<string-name>
<surname>Bras</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Martin&#x02010;Lanneree</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Gobert</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Auge</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Breig</surname>, <given-names>O.</given-names>
</string-name>, <string-name>
<surname>Sanial</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Yamaguchi</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Haenlin</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Plessis</surname>, <given-names>A.</given-names>
</string-name> &#x00026; <string-name>
<surname>Waltzer</surname>, <given-names>L.</given-names>
</string-name> (<year>2012</year>) <article-title>Myeloid leukemia factor is a conserved regulator of RUNX transcription factor activity involved in hematopoiesis</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source>, <volume>109</volume>, <fpage>4986</fpage>&#x02013;<lpage>4991</lpage>.<pub-id pub-id-type="pmid">22411814</pub-id></mixed-citation></ref><ref id="bjh13613-bib-0005"><mixed-citation publication-type="journal" id="bjh13613-cit-0005">
<string-name>
<surname>Coustan&#x02010;Smith</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Mullighan</surname>, <given-names>C.G.</given-names>
</string-name>, <string-name>
<surname>Onciu</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Behm</surname>, <given-names>F.G.</given-names>
</string-name>, <string-name>
<surname>Raimondi</surname>, <given-names>S.C.</given-names>
</string-name>, <string-name>
<surname>Pei</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Su</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Rubnitz</surname>, <given-names>J.E.</given-names>
</string-name>, <string-name>
<surname>Basso</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Biondi</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Pui</surname>, <given-names>C.H.</given-names>
</string-name>, <string-name>
<surname>Downing</surname>, <given-names>J.R.</given-names>
</string-name> &#x00026; <string-name>
<surname>Campana</surname>, <given-names>D.</given-names>
</string-name> (<year>2009</year>) <article-title>Early T&#x02010;cell precursor leukaemia: a subtype of very high&#x02010;risk acute lymphoblastic leukaemia</article-title>. <source>Lancet Oncology</source>, <volume>10</volume>, <fpage>147</fpage>&#x02013;<lpage>156</lpage>.<pub-id pub-id-type="pmid">19147408</pub-id></mixed-citation></ref><ref id="bjh13613-bib-0006"><mixed-citation publication-type="journal" id="bjh13613-cit-0006">
<string-name>
<surname>De Braekeleer</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Meyer</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Le Bris</surname>, <given-names>M.J.</given-names>
</string-name>, <string-name>
<surname>Douet&#x02010;Guilbert</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Basinko</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Morel</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Berthou</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Marschalek</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Ferec</surname>, <given-names>C.</given-names>
</string-name> &#x00026; <string-name>
<surname>De Braekeleer</surname>, <given-names>M.</given-names>
</string-name> (<year>2010</year>) <article-title>Identification of a MLL&#x02010;MLLT4 fusion gene resulting from a t(6;11)(q27;q23) presenting as a del(11q) in a child with T&#x02010;cell acute lymphoblastic leukemia</article-title>. <source>Leukaemia &#x00026; Lymphoma</source>, <volume>51</volume>, <fpage>1570</fpage>&#x02013;<lpage>1573</lpage>.</mixed-citation></ref><ref id="bjh13613-bib-0007"><mixed-citation publication-type="journal" id="bjh13613-cit-0007">
<string-name>
<surname>van Dongen</surname>, <given-names>J.J.</given-names>
</string-name>, <string-name>
<surname>Langerak</surname>, <given-names>A.W.</given-names>
</string-name>, <string-name>
<surname>Bruggemann</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Evans</surname>, <given-names>P.A.</given-names>
</string-name>, <string-name>
<surname>Hummel</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Lavender</surname>, <given-names>F.L.</given-names>
</string-name>, <string-name>
<surname>Delabesse</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Davi</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Schuuring</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Garcia&#x02010;Sanz</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>van Krieken</surname>, <given-names>J.H.</given-names>
</string-name>, <string-name>
<surname>Droese</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Gonzalez</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Bastard</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>White</surname>, <given-names>H.E.</given-names>
</string-name>, <string-name>
<surname>Spaargaren</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Gonzalez</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Parreira</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Smith</surname>, <given-names>J.L.</given-names>
</string-name>, <string-name>
<surname>Morgan</surname>, <given-names>G.J.</given-names>
</string-name>, <string-name>
<surname>Kneba</surname>, <given-names>M.</given-names>
</string-name> &#x00026; <string-name>
<surname>Macintyre</surname>, <given-names>E.A.</given-names>
</string-name> (<year>2003</year>) <article-title>Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T&#x02010;cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED&#x02010;2 Concerted Action BMH4&#x02010;CT98&#x02010;3936</article-title>. <source>Leukemia</source>, <volume>17</volume>, <fpage>2257</fpage>&#x02013;<lpage>2317</lpage>.<pub-id pub-id-type="pmid">14671650</pub-id></mixed-citation></ref><ref id="bjh13613-bib-0008"><mixed-citation publication-type="journal" id="bjh13613-cit-0008">
<string-name>
<surname>Edelmann</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Holzmann</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Miller</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Winkler</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Buhler</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Zenz</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Bullinger</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Kuhn</surname>, <given-names>M.W.</given-names>
</string-name>, <string-name>
<surname>Gerhardinger</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Bloehdorn</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Radtke</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Su</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Ma</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Pounds</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Hallek</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Lichter</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Korbel</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Busch</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Mertens</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Downing</surname>, <given-names>J.R.</given-names>
</string-name>, <string-name>
<surname>Stilgenbauer</surname>, <given-names>S.</given-names>
</string-name> &#x00026; <string-name>
<surname>Dohner</surname>, <given-names>H.</given-names>
</string-name> (<year>2012</year>) <article-title>High&#x02010;resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations</article-title>. <source>Blood</source>, <volume>120</volume>, <fpage>4783</fpage>&#x02013;<lpage>4794</lpage>.<pub-id pub-id-type="pmid">23047824</pub-id></mixed-citation></ref><ref id="bjh13613-bib-0009"><mixed-citation publication-type="journal" id="bjh13613-cit-0009">
<string-name>
<surname>Eguchi&#x02010;Ishimae</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Eguchi</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Kempski</surname>, <given-names>H.</given-names>
</string-name> &#x00026; <string-name>
<surname>Greaves</surname>, <given-names>M.</given-names>
</string-name> (<year>2008</year>) <article-title>NOTCH1 mutation can be an early, prenatal genetic event in T&#x02010;ALL</article-title>. <source>Blood</source>, <volume>111</volume>, <fpage>376</fpage>&#x02013;<lpage>378</lpage>.<pub-id pub-id-type="pmid">17901244</pub-id></mixed-citation></ref><ref id="bjh13613-bib-0010"><mixed-citation publication-type="journal" id="bjh13613-cit-0010">
<string-name>
<surname>Emerenciano</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Agudelo Arias</surname>, <given-names>D.P.</given-names>
</string-name>, <string-name>
<surname>Coser</surname>, <given-names>V.M.</given-names>
</string-name>, <string-name>
<surname>de Brito</surname>, <given-names>G.D.</given-names>
</string-name>, <string-name>
<surname>Macedo Silva</surname>, <given-names>M.L.</given-names>
</string-name> &#x00026; <string-name>
<surname>Pombo&#x02010;de&#x02010;Oliveira</surname>, <given-names>M.S.</given-names>
</string-name> (<year>2006</year>) <article-title>Molecular cytogenetic findings of acute leukemia included in the Brazilian Collaborative Study Group of Infant acute leukemia</article-title>. <source>Pediatric Blood &#x00026; Cancer</source>, <volume>47</volume>, <fpage>549</fpage>&#x02013;<lpage>554</lpage>.<pub-id pub-id-type="pmid">16261608</pub-id></mixed-citation></ref><ref id="bjh13613-bib-0011"><mixed-citation publication-type="journal" id="bjh13613-cit-0011">
<string-name>
<surname>Emerenciano</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Meyer</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Mansur</surname>, <given-names>M.B.</given-names>
</string-name>, <string-name>
<surname>Marschalek</surname>, <given-names>R.</given-names>
</string-name> &#x00026; <string-name>
<surname>de Pombo&#x02010; Oliveira</surname>, <given-names>M.S.</given-names>
</string-name> &#x00026; <collab collab-type="authors">Brazilian Collaborative Study Group of Infant Acute Leukaemia</collab>
(<year>2013</year>) <article-title>The distribution of MLL breakpoints correlates with outcome in infant acute leukaemia</article-title>. <source>British Journal of Haematology</source>, <volume>161</volume>, <fpage>224</fpage>&#x02013;<lpage>236</lpage>.<pub-id pub-id-type="pmid">23432364</pub-id></mixed-citation></ref><ref id="bjh13613-bib-0012"><mixed-citation publication-type="journal" id="bjh13613-cit-0012">
<string-name>
<surname>Ford</surname>, <given-names>A.M.</given-names>
</string-name>, <string-name>
<surname>Ridge</surname>, <given-names>S.A.</given-names>
</string-name>, <string-name>
<surname>Cabrera</surname>, <given-names>M.E.</given-names>
</string-name>, <string-name>
<surname>Mahmoud</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Steel</surname>, <given-names>C.M.</given-names>
</string-name>, <string-name>
<surname>Chan</surname>, <given-names>L.C.</given-names>
</string-name> &#x00026; <string-name>
<surname>Greaves</surname>, <given-names>M.</given-names>
</string-name> (<year>1993</year>) <article-title>
<italic>In utero</italic> rearrangements in the trithorax&#x02010;related oncogene in infant leukaemias</article-title>. <source>Nature</source>, <volume>363</volume>, <fpage>358</fpage>&#x02013;<lpage>360</lpage>.<pub-id pub-id-type="pmid">8497319</pub-id></mixed-citation></ref><ref id="bjh13613-bib-0013"><mixed-citation publication-type="journal" id="bjh13613-cit-0013">
<string-name>
<surname>Ford</surname>, <given-names>A.M.</given-names>
</string-name>, <string-name>
<surname>Pombo&#x02010;de&#x02010;Oliveira</surname>, <given-names>M.S.</given-names>
</string-name>, <string-name>
<surname>McCarthy</surname>, <given-names>K.P.</given-names>
</string-name>, <string-name>
<surname>MacLean</surname>, <given-names>J.M.</given-names>
</string-name>, <string-name>
<surname>Carrico</surname>, <given-names>K.C.</given-names>
</string-name>, <string-name>
<surname>Vincent</surname>, <given-names>R.F.</given-names>
</string-name> &#x00026; <string-name>
<surname>Greaves</surname>, <given-names>M.</given-names>
</string-name> (<year>1997</year>) <article-title>Monoclonal origin of concordant T&#x02010;cell malignancy in identical twins</article-title>. <source>Blood</source>, <volume>89</volume>, <fpage>281</fpage>&#x02013;<lpage>285</lpage>.<pub-id pub-id-type="pmid">8978302</pub-id></mixed-citation></ref><ref id="bjh13613-bib-0014"><mixed-citation publication-type="journal" id="bjh13613-cit-0014">
<string-name>
<surname>Gale</surname>, <given-names>K.B.</given-names>
</string-name>, <string-name>
<surname>Ford</surname>, <given-names>A.M.</given-names>
</string-name>, <string-name>
<surname>Repp</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Borkhardt</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Keller</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Eden</surname>, <given-names>O.B.</given-names>
</string-name> &#x00026; <string-name>
<surname>Greaves</surname>, <given-names>M.F.</given-names>
</string-name> (<year>1997</year>) <article-title>Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source>, <volume>94</volume>, <fpage>13950</fpage>&#x02013;<lpage>13954</lpage>.<pub-id pub-id-type="pmid">9391133</pub-id></mixed-citation></ref><ref id="bjh13613-bib-0015"><mixed-citation publication-type="journal" id="bjh13613-cit-0015">
<string-name>
<surname>Gutierrez</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Sanda</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Grebliunaite</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Carracedo</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Salmena</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Ahn</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Dahlberg</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Neuberg</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Moreau</surname>, <given-names>L.A.</given-names>
</string-name>, <string-name>
<surname>Winter</surname>, <given-names>S.S.</given-names>
</string-name>, <string-name>
<surname>Larson</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Protopopov</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Chin</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Pandolfi</surname>, <given-names>P.P.</given-names>
</string-name>, <string-name>
<surname>Silverman</surname>, <given-names>L.B.</given-names>
</string-name>, <string-name>
<surname>Hunger</surname>, <given-names>S.P.</given-names>
</string-name>, <string-name>
<surname>Sallan</surname>, <given-names>S.E.</given-names>
</string-name> &#x00026; <string-name>
<surname>Look</surname>, <given-names>A.T.</given-names>
</string-name> (<year>2009</year>) <article-title>High frequency of PTEN, PI3K, and AKT abnormalities in T&#x02010;cell acute lymphoblastic leukemia</article-title>. <source>Blood</source>, <volume>114</volume>, <fpage>647</fpage>&#x02013;<lpage>650</lpage>.<pub-id pub-id-type="pmid">19458356</pub-id></mixed-citation></ref><ref id="bjh13613-bib-0016"><mixed-citation publication-type="journal" id="bjh13613-cit-0016">
<string-name>
<surname>Hanahan</surname>, <given-names>D.</given-names>
</string-name> &#x00026; <string-name>
<surname>Weinberg</surname>, <given-names>R.A.</given-names>
</string-name> (<year>2011</year>) <article-title>Hallmarks of cancer: the next generation</article-title>. <source>Cell</source>, <volume>144</volume>, <fpage>646</fpage>&#x02013;<lpage>674</lpage>.<pub-id pub-id-type="pmid">21376230</pub-id></mixed-citation></ref><ref id="bjh13613-bib-0017"><mixed-citation publication-type="journal" id="bjh13613-cit-0017">
<string-name>
<surname>Langerak</surname>, <given-names>A.W.</given-names>
</string-name>, <string-name>
<surname>Groenen</surname>, <given-names>P.J.</given-names>
</string-name>, <string-name>
<surname>Bruggemann</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Beldjord</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Bellan</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Bonello</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Boone</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Carter</surname>, <given-names>G.I.</given-names>
</string-name>, <string-name>
<surname>Catherwood</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Davi</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Delfau&#x02010;Larue</surname>, <given-names>M.H.</given-names>
</string-name>, <string-name>
<surname>Diss</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Evans</surname>, <given-names>P.A.</given-names>
</string-name>, <string-name>
<surname>Gameiro</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Garcia Sanz</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Gonzalez</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Grand</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Hakansson</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Hummel</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Lombardia</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Macintyre</surname>, <given-names>E.A.</given-names>
</string-name>, <string-name>
<surname>Milner</surname>, <given-names>B.J.</given-names>
</string-name>, <string-name>
<surname>Montes&#x02010;Moreno</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Schuuring</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Spaargaren</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Hodges</surname>, <given-names>E.</given-names>
</string-name> &#x00026; <string-name>
<surname>van Dongen</surname>, <given-names>J.J.</given-names>
</string-name> (<year>2012</year>) <article-title>EuroClonality/BIOMED&#x02010;2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations</article-title>. <source>Leukemia</source>, <volume>26</volume>, <fpage>2159</fpage>&#x02013;<lpage>2171</lpage>.<pub-id pub-id-type="pmid">22918122</pub-id></mixed-citation></ref><ref id="bjh13613-bib-0018"><mixed-citation publication-type="journal" id="bjh13613-cit-0018">
<string-name>
<surname>Lecuyer</surname>, <given-names>E.</given-names>
</string-name> &#x00026; <string-name>
<surname>Hoang</surname>, <given-names>T.</given-names>
</string-name> (<year>2004</year>) <article-title>SCL: from the origin of hematopoiesis to stem cells and leukemia</article-title>. <source>Experimental Hematology</source>, <volume>32</volume>, <fpage>11</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="pmid">14725896</pub-id></mixed-citation></ref><ref id="bjh13613-bib-0019"><mixed-citation publication-type="journal" id="bjh13613-cit-0019">
<string-name>
<surname>Ma</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Dobbins</surname>, <given-names>S.E.</given-names>
</string-name>, <string-name>
<surname>Sherborne</surname>, <given-names>A.L.</given-names>
</string-name>, <string-name>
<surname>Chubb</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Galbiati</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Cazzaniga</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Micalizzi</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Tearle</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Lloyd</surname>, <given-names>A.L.</given-names>
</string-name>, <string-name>
<surname>Hain</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Greaves</surname>, <given-names>M.</given-names>
</string-name> &#x00026; <string-name>
<surname>Houlston</surname>, <given-names>R.S.</given-names>
</string-name> (<year>2013</year>) <article-title>Developmental timing of mutations revealed by whole&#x02010;genome sequencing of twins with acute lymphoblastic leukemia</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source>, <volume>110</volume>, <fpage>7429</fpage>&#x02013;<lpage>7433</lpage>.<pub-id pub-id-type="pmid">23569245</pub-id></mixed-citation></ref><ref id="bjh13613-bib-0020"><mixed-citation publication-type="journal" id="bjh13613-cit-0020">
<string-name>
<surname>Mansur</surname>, <given-names>M.B.</given-names>
</string-name>, <string-name>
<surname>Emerenciano</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Brewer</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Sant'Ana</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Mendonca</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Thuler</surname>, <given-names>L.C.</given-names>
</string-name>, <string-name>
<surname>Koifman</surname>, <given-names>S.</given-names>
</string-name> &#x00026; <string-name>
<surname>de Pombo&#x02010; &#x02010;Oliveira</surname>, <given-names>M.S.</given-names>
</string-name> (<year>2009</year>) <article-title>SIL&#x02010;TAL1 fusion gene negative impact in T&#x02010;cell acute lymphoblastic leukemia outcome</article-title>. <source>Leukaemia &#x00026; Lymphoma</source>, <volume>50</volume>, <fpage>1318</fpage>&#x02013;<lpage>1325</lpage>.</mixed-citation></ref><ref id="bjh13613-bib-0021"><mixed-citation publication-type="journal" id="bjh13613-cit-0021">
<string-name>
<surname>Mansur</surname>, <given-names>M.B.</given-names>
</string-name>, <string-name>
<surname>Emerenciano</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Splendore</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Brewer</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Hassan</surname>, <given-names>R.</given-names>
</string-name> &#x00026; <string-name>
<surname>Pombo&#x02010;de&#x02010;Oliveira</surname>, <given-names>M.S.</given-names>
</string-name> (<year>2010</year>) <article-title>T&#x02010;cell lymphoblastic leukemia in early childhood presents NOTCH1 mutations and MLL rearrangements</article-title>. <source>Leukemia Research</source>, <volume>34</volume>, <fpage>483</fpage>&#x02013;<lpage>486</lpage>.<pub-id pub-id-type="pmid">19631984</pub-id></mixed-citation></ref><ref id="bjh13613-bib-0022"><mixed-citation publication-type="journal" id="bjh13613-cit-0022">
<string-name>
<surname>Mansur</surname>, <given-names>M.B.</given-names>
</string-name>, <string-name>
<surname>Hassan</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Barbosa</surname>, <given-names>T.C.</given-names>
</string-name>, <string-name>
<surname>Splendore</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Jotta</surname>, <given-names>P.Y.</given-names>
</string-name>, <string-name>
<surname>Yunes</surname>, <given-names>J.A.</given-names>
</string-name>, <string-name>
<surname>Wiemels</surname>, <given-names>J.L.</given-names>
</string-name> &#x00026; <string-name>
<surname>Pombo&#x02010;de&#x02010;Oliveira</surname>, <given-names>M.S.</given-names>
</string-name> (<year>2012</year>) <article-title>Impact of complex NOTCH1 mutations on survival in paediatric T&#x02010;cell leukaemia</article-title>. <source>BMC Cancer</source>, <volume>12</volume>, <fpage>9</fpage>.<pub-id pub-id-type="pmid">22225590</pub-id></mixed-citation></ref><ref id="bjh13613-bib-0023"><mixed-citation publication-type="journal" id="bjh13613-cit-0023">
<string-name>
<surname>Mendes</surname>, <given-names>R.D.</given-names>
</string-name>, <string-name>
<surname>Sarmento</surname>, <given-names>L.M.</given-names>
</string-name>, <string-name>
<surname>Cante&#x02010;Barrett</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Zuurbier</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Buijs&#x02010;Gladdines</surname>, <given-names>J.G.</given-names>
</string-name>, <string-name>
<surname>Povoa</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Smits</surname>, <given-names>W.K.</given-names>
</string-name>, <string-name>
<surname>Abecasis</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Yunes</surname>, <given-names>J.A.</given-names>
</string-name>, <string-name>
<surname>Sonneveld</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Horstmann</surname>, <given-names>M.A.</given-names>
</string-name>, <string-name>
<surname>Pieters</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Barata</surname>, <given-names>J.T.</given-names>
</string-name> &#x00026; <string-name>
<surname>Meijerink</surname>, <given-names>J.P.</given-names>
</string-name> (<year>2014</year>) <article-title>PTEN microdeletions in T&#x02010;cell acute lymphoblastic leukemia are caused by illegitimate RAG&#x02010;mediated recombination events</article-title>. <source>Blood</source>, <volume>124</volume>, <fpage>567</fpage>&#x02013;<lpage>578</lpage>.<pub-id pub-id-type="pmid">24904117</pub-id></mixed-citation></ref><ref id="bjh13613-bib-0024"><mixed-citation publication-type="journal" id="bjh13613-cit-0024">
<string-name>
<surname>Mullighan</surname>, <given-names>C.G.</given-names>
</string-name>, <string-name>
<surname>Goorha</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Radtke</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Miller</surname>, <given-names>C.B.</given-names>
</string-name>, <string-name>
<surname>Coustan&#x02010;Smith</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Dalton</surname>, <given-names>J.D.</given-names>
</string-name>, <string-name>
<surname>Girtman</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Mathew</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Ma</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Pounds</surname>, <given-names>S.B.</given-names>
</string-name>, <string-name>
<surname>Su</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Pui</surname>, <given-names>C.H.</given-names>
</string-name>, <string-name>
<surname>Relling</surname>, <given-names>M.V.</given-names>
</string-name>, <string-name>
<surname>Evans</surname>, <given-names>W.E.</given-names>
</string-name>, <string-name>
<surname>Shurtleff</surname>, <given-names>S.A.</given-names>
</string-name> &#x00026; <string-name>
<surname>Downing</surname>, <given-names>J.R.</given-names>
</string-name> (<year>2007</year>) <article-title>Genome&#x02010;wide analysis of genetic alterations in acute lymphoblastic leukaemia</article-title>. <source>Nature</source>, <volume>446</volume>, <fpage>758</fpage>&#x02013;<lpage>764</lpage>.<pub-id pub-id-type="pmid">17344859</pub-id></mixed-citation></ref><ref id="bjh13613-bib-0025"><mixed-citation publication-type="journal" id="bjh13613-cit-0025">
<string-name>
<surname>Mullighan</surname>, <given-names>C.G.</given-names>
</string-name>, <string-name>
<surname>Phillips</surname>, <given-names>L.A.</given-names>
</string-name>, <string-name>
<surname>Su</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Ma</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Miller</surname>, <given-names>C.B.</given-names>
</string-name>, <string-name>
<surname>Shurtleff</surname>, <given-names>S.A.</given-names>
</string-name> &#x00026; <string-name>
<surname>Downing</surname>, <given-names>J.R.</given-names>
</string-name> (<year>2008</year>) <article-title>Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia</article-title>. <source>Science</source>, <volume>322</volume>, <fpage>1377</fpage>&#x02013;<lpage>1380</lpage>.<pub-id pub-id-type="pmid">19039135</pub-id></mixed-citation></ref><ref id="bjh13613-bib-0026"><mixed-citation publication-type="journal" id="bjh13613-cit-0026">
<string-name>
<surname>Okamoto</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Ogawa</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Nowak</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Kawamata</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Akagi</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Kato</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Sanada</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Weiss</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Haferlach</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Dugas</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Ruckert</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Haferlach</surname>, <given-names>T.</given-names>
</string-name> &#x00026; <string-name>
<surname>Koeffler</surname>, <given-names>H.P.</given-names>
</string-name> (<year>2010</year>) <article-title>Genomic profiling of adult acute lymphoblastic leukemia by single nucleotide polymorphism oligonucleotide microarray and comparison to pediatric acute lymphoblastic leukemia</article-title>. <source>Haematologica</source>, <volume>95</volume>, <fpage>1481</fpage>&#x02013;<lpage>1488</lpage>.<pub-id pub-id-type="pmid">20435627</pub-id></mixed-citation></ref><ref id="bjh13613-bib-0027"><mixed-citation publication-type="journal" id="bjh13613-cit-0027">
<string-name>
<surname>Pui</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Relling</surname>, <given-names>M.V.</given-names>
</string-name> &#x00026; <string-name>
<surname>Downing</surname>, <given-names>J.R.</given-names>
</string-name> (<year>2004</year>) <article-title>Mechanisms of disease: acute lymphoblastic leukemia</article-title>. <source>New England Journal of Medicine</source>, <volume>350</volume>, <fpage>1535</fpage>&#x02013;<lpage>1548</lpage>.<pub-id pub-id-type="pmid">15071128</pub-id></mixed-citation></ref><ref id="bjh13613-bib-0028"><mixed-citation publication-type="journal" id="bjh13613-cit-0028">
<string-name>
<surname>Schwab</surname>, <given-names>C.J.</given-names>
</string-name>, <string-name>
<surname>Chilton</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Morrison</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Jones</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Al&#x02010;Shehhi</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Erhorn</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Russell</surname>, <given-names>L.J.</given-names>
</string-name>, <string-name>
<surname>Moorman</surname>, <given-names>A.V.</given-names>
</string-name> &#x00026; <string-name>
<surname>Harrison</surname>, <given-names>C.J.</given-names>
</string-name> (<year>2013</year>) <article-title>Genes commonly deleted in childhood B&#x02010;cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features</article-title>. <source>Haematologica</source>, <volume>98</volume>, <fpage>1081</fpage>&#x02013;<lpage>1088</lpage>.<pub-id pub-id-type="pmid">23508010</pub-id></mixed-citation></ref><ref id="bjh13613-bib-0029"><mixed-citation publication-type="journal" id="bjh13613-cit-0029">
<string-name>
<surname>Skowronska</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Parker</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Ahmed</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Oldreive</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Davis</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Richards</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Dyer</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Matutes</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Gonzalez</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Taylor</surname>, <given-names>A.M.</given-names>
</string-name>, <string-name>
<surname>Moss</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Oscier</surname>, <given-names>D.</given-names>
</string-name> &#x00026; <string-name>
<surname>Stankovic</surname>, <given-names>T.</given-names>
</string-name> (<year>2012</year>) <article-title>Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial</article-title>. <source>Journal of Clinical Oncology</source>, <volume>30</volume>, <fpage>4524</fpage>&#x02013;<lpage>4532</lpage>.<pub-id pub-id-type="pmid">23091097</pub-id></mixed-citation></ref><ref id="bjh13613-bib-0030"><mixed-citation publication-type="journal" id="bjh13613-cit-0030">
<string-name>
<surname>Szczepanski</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>van der Velden</surname>, <given-names>V.H.</given-names>
</string-name>, <string-name>
<surname>Waanders</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Kuiper</surname>, <given-names>R.P.</given-names>
</string-name>, <string-name>
<surname>Van Vlierberghe</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Gruhn</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Eckert</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Panzer&#x02010;Grumayer</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Basso</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Cave</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Stadt</surname>, <given-names>U.Z.</given-names>
</string-name>, <string-name>
<surname>Campana</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Schrauder</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Sutton</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>van Wering</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Meijerink</surname>, <given-names>J.P.</given-names>
</string-name> &#x00026; <string-name>
<surname>van Dongen</surname>, <given-names>J.J.</given-names>
</string-name> (<year>2011</year>) <article-title>Late recurrence of childhood T&#x02010;cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition</article-title>. <source>Journal of Clinical Oncology</source>, <volume>29</volume>, <fpage>1643</fpage>&#x02013;<lpage>1649</lpage>.<pub-id pub-id-type="pmid">21357790</pub-id></mixed-citation></ref><ref id="bjh13613-bib-0031"><mixed-citation publication-type="journal" id="bjh13613-cit-0031">
<string-name>
<surname>Valentine</surname>, <given-names>M.C.</given-names>
</string-name>, <string-name>
<surname>Linabery</surname>, <given-names>A.M.</given-names>
</string-name>, <string-name>
<surname>Chasnoff</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Hughes</surname>, <given-names>A.E.</given-names>
</string-name>, <string-name>
<surname>Mallaney</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Sanchez</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Giacalone</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Heerema</surname>, <given-names>N.A.</given-names>
</string-name>, <string-name>
<surname>Hilden</surname>, <given-names>J.M.</given-names>
</string-name>, <string-name>
<surname>Spector</surname>, <given-names>L.G.</given-names>
</string-name>, <string-name>
<surname>Ross</surname>, <given-names>J.A.</given-names>
</string-name> &#x00026; <string-name>
<surname>Druley</surname>, <given-names>T.E.</given-names>
</string-name> (<year>2014</year>) <article-title>Excess congenital non&#x02010;synonymous variation in leukemia&#x02010;associated genes in MLL&#x02010; infant leukemia: a Children's Oncology Group report</article-title>. <source>Leukemia</source>, <volume>28</volume>, <fpage>1235</fpage>&#x02013;<lpage>1241</lpage>.<pub-id pub-id-type="pmid">24301523</pub-id></mixed-citation></ref><ref id="bjh13613-bib-0032"><mixed-citation publication-type="journal" id="bjh13613-cit-0032">
<string-name>
<surname>Van Vlierberghe</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>van Grotel</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Beverloo</surname>, <given-names>H.B.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Helgason</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Buijs&#x02010;Gladdines</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Passier</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>van Wering</surname>, <given-names>E.R.</given-names>
</string-name>, <string-name>
<surname>Veerman</surname>, <given-names>A.J.</given-names>
</string-name>, <string-name>
<surname>Kamps</surname>, <given-names>W.A.</given-names>
</string-name>, <string-name>
<surname>Meijerink</surname>, <given-names>J.P.</given-names>
</string-name> &#x00026; <string-name>
<surname>Pieters</surname>, <given-names>R.</given-names>
</string-name> (<year>2006</year>) <article-title>The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T&#x02010;cell acute lymphoblastic leukemia</article-title>. <source>Blood</source>, <volume>108</volume>, <fpage>3520</fpage>&#x02013;<lpage>3529</lpage>.<pub-id pub-id-type="pmid">16873670</pub-id></mixed-citation></ref><ref id="bjh13613-bib-0033"><mixed-citation publication-type="journal" id="bjh13613-cit-0033">
<string-name>
<surname>Weng</surname>, <given-names>A.P.</given-names>
</string-name>, <string-name>
<surname>Ferrando</surname>, <given-names>A.A.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Morris</surname>, <given-names>J.P.t.</given-names>
</string-name>, <string-name>
<surname>Silverman</surname>, <given-names>L.B.</given-names>
</string-name>, <string-name>
<surname>Sanchez&#x02010;Irizarry</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Blacklow</surname>, <given-names>S.C.</given-names>
</string-name>, <string-name>
<surname>Look</surname>, <given-names>A.T.</given-names>
</string-name> &#x00026; <string-name>
<surname>Aster</surname>, <given-names>J.C.</given-names>
</string-name> (<year>2004</year>) <article-title>Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia</article-title>. <source>Science</source>, <volume>306</volume>, <fpage>269</fpage>&#x02013;<lpage>271</lpage>.<pub-id pub-id-type="pmid">15472075</pub-id></mixed-citation></ref><ref id="bjh13613-bib-0034"><mixed-citation publication-type="journal" id="bjh13613-cit-0034">
<string-name>
<surname>Yoneda&#x02010;Kato</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Tomoda</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Umehara</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Arata</surname>, <given-names>Y.</given-names>
</string-name> &#x00026; <string-name>
<surname>Kato</surname>, <given-names>J.Y.</given-names>
</string-name> (<year>2005</year>) <article-title>Myeloid leukemia factor 1 regulates p53 by suppressing COP1 via COP9 signalosome subunit 3</article-title>. <source>EMBO Journal</source>, <volume>24</volume>, <fpage>1739</fpage>&#x02013;<lpage>1749</lpage>.<pub-id pub-id-type="pmid">15861129</pub-id></mixed-citation></ref><ref id="bjh13613-bib-0035"><mixed-citation publication-type="journal" id="bjh13613-cit-0035">
<string-name>
<surname>Zenatti</surname>, <given-names>P.P.</given-names>
</string-name>, <string-name>
<surname>Ribeiro</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Zuurbier</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Silva</surname>, <given-names>M.C.</given-names>
</string-name>, <string-name>
<surname>Paganin</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Tritapoe</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Hixon</surname>, <given-names>J.A.</given-names>
</string-name>, <string-name>
<surname>Silveira</surname>, <given-names>A.B.</given-names>
</string-name>, <string-name>
<surname>Cardoso</surname>, <given-names>B.A.</given-names>
</string-name>, <string-name>
<surname>Sarmento</surname>, <given-names>L.M.</given-names>
</string-name>, <string-name>
<surname>Correia</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Toribio</surname>, <given-names>M.L.</given-names>
</string-name>, <string-name>
<surname>Kobarg</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Horstmann</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Pieters</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Brandalise</surname>, <given-names>S.R.</given-names>
</string-name>, <string-name>
<surname>Ferrando</surname>, <given-names>A.A.</given-names>
</string-name>, <string-name>
<surname>Meijerink</surname>, <given-names>J.P.</given-names>
</string-name>, <string-name>
<surname>Durum</surname>, <given-names>S.K.</given-names>
</string-name>, <string-name>
<surname>Yunes</surname>, <given-names>J.A.</given-names>
</string-name> &#x00026; <string-name>
<surname>Barata</surname>, <given-names>J.T.</given-names>
</string-name> (<year>2011</year>) <article-title>Oncogenic IL7R gain&#x02010;of&#x02010;function mutations in childhood T&#x02010;cell acute lymphoblastic leukemia</article-title>. <source>Nature Genetics</source>, <volume>43</volume>, <fpage>932</fpage>&#x02013;<lpage>939</lpage>.<pub-id pub-id-type="pmid">21892159</pub-id></mixed-citation></ref><ref id="bjh13613-bib-0036"><mixed-citation publication-type="journal" id="bjh13613-cit-0036">
<string-name>
<surname>Zhang</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Ding</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Holmfeldt</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Wu</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Heatley</surname>, <given-names>S.L.</given-names>
</string-name>, <string-name>
<surname>Payne&#x02010;Turner</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Easton</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Rusch</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Lu</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>S.C.</given-names>
</string-name>, <string-name>
<surname>Wei</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Collins&#x02010;Underwood</surname>, <given-names>J.R.</given-names>
</string-name>, <string-name>
<surname>Ma</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Roberts</surname>, <given-names>K.G.</given-names>
</string-name>, <string-name>
<surname>Pounds</surname>, <given-names>S.B.</given-names>
</string-name>, <string-name>
<surname>Ulyanov</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Becksfort</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Gupta</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Huether</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Kriwacki</surname>, <given-names>R.W.</given-names>
</string-name>, <string-name>
<surname>Parker</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>McGoldrick</surname>, <given-names>D.J.</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Alford</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Espy</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Bobba</surname>, <given-names>K.C.</given-names>
</string-name>, <string-name>
<surname>Song</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Pei</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Roberts</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Barbato</surname>, <given-names>M.I.</given-names>
</string-name>, <string-name>
<surname>Campana</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Coustan&#x02010;Smith</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Shurtleff</surname>, <given-names>S.A.</given-names>
</string-name>, <string-name>
<surname>Raimondi</surname>, <given-names>S.C.</given-names>
</string-name>, <string-name>
<surname>Kleppe</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Cools</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Shimano</surname>, <given-names>K.A.</given-names>
</string-name>, <string-name>
<surname>Hermiston</surname>, <given-names>M.L.</given-names>
</string-name>, <string-name>
<surname>Doulatov</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Eppert</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Laurenti</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Notta</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Dick</surname>, <given-names>J.E.</given-names>
</string-name>, <string-name>
<surname>Basso</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Hunger</surname>, <given-names>S.P.</given-names>
</string-name>, <string-name>
<surname>Loh</surname>, <given-names>M.L.</given-names>
</string-name>, <string-name>
<surname>Devidas</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Wood</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Winter</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Dunsmore</surname>, <given-names>K.P.</given-names>
</string-name>, <string-name>
<surname>Fulton</surname>, <given-names>R.S.</given-names>
</string-name>, <string-name>
<surname>Fulton</surname>, <given-names>L.L.</given-names>
</string-name>, <string-name>
<surname>Hong</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Harris</surname>, <given-names>C.C.</given-names>
</string-name>, <string-name>
<surname>Dooling</surname>, <given-names>D.J.</given-names>
</string-name>, <string-name>
<surname>Ochoa</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>, <given-names>K.J.</given-names>
</string-name>, <string-name>
<surname>Obenauer</surname>, <given-names>J.C.</given-names>
</string-name>, <string-name>
<surname>Evans</surname>, <given-names>W.E.</given-names>
</string-name>, <string-name>
<surname>Pui</surname>, <given-names>C.H.</given-names>
</string-name>, <string-name>
<surname>Naeve</surname>, <given-names>C.W.</given-names>
</string-name>, <string-name>
<surname>Ley</surname>, <given-names>T.J.</given-names>
</string-name>, <string-name>
<surname>Mardis</surname>, <given-names>E.R.</given-names>
</string-name>, <string-name>
<surname>Wilson</surname>, <given-names>R.K.</given-names>
</string-name>, <string-name>
<surname>Downing</surname>, <given-names>J.R.</given-names>
</string-name> &#x00026; <string-name>
<surname>Mullighan</surname>, <given-names>C.G.</given-names>
</string-name> (<year>2012</year>) <article-title>The genetic basis of early T&#x02010;cell precursor acute lymphoblastic leukaemia</article-title>. <source>Nature</source>, <volume>481</volume>, <fpage>157</fpage>&#x02013;<lpage>163</lpage>.<pub-id pub-id-type="pmid">22237106</pub-id></mixed-citation></ref></ref-list></back></article>